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Chair: Mark E. Meyerhoff 
 
 
One of the greatest technological challenges of implantable biosensors is the 
biocompatibility problem that arises after implantation.  Nitric oxide (NO) is known as a 
potent anti-thrombus and anti-inflammatory agent released by healthy endothelial cells.  
Hence, this dissertation research focuses on developing novel NO releasing/generating 
coatings to enhance the biocompatibility of implantable glucose/lactate sensors.  A non-
invasive method for detecting tear glucose levels is also proposed as a potential substitute 




Novel NO releasing coatings are developed by doping poly(lactide-co-glycolide) 







 for at least 7 days.  Intravenous amperometric needle-type glucose/lactate 
sensors prepared with such coatings have excellent in vitro analytical performance.  
Glucose sensors with NO release show significantly enhanced hemocompatibility when 
implanted in rabbit veins for 8 h, with minimized thrombus formation on their surfaces 
and greater accuracy in measuring blood glucose levels, as evaluated using a Clarke error 
grid analysis. 
 
Nitric oxide generating coatings, including Cu(II)-cyclen polyurethanes, Cu
0
 
nanoparticle-doped polyurethanes and 100 bilayers of organoselenium-linked 
polyethyleneimine (SePEI) and alginate (Alg), are employed on glucose/lactate sensors.  
These coatings all enable the sensors to generate NO from endogenous S-nitrosothiols 
(RSNOs), but there is some influence on the analytical performance of the sensors.  
Preliminary in vivo experiments indicated the possible need for additional RSNOs to 
generate sufficient NO fluxes. 
 
An amperometric needle-type tear glucose sensor is described and employed in 
conjunction with a 0.84 mm i.d. capillary tube to collect 4-5 μL tear fluid.  The sensor 
possesses excellent selectivity for glucose over potential electroactive interferent species, 
including ascorbic acid and uric acid.  Further, the new sensor is optimized to achieve 
very low detection limits of 1.5 ± 0.4 μM of glucose (S/N=3) with a sensitivity of 0.019 ± 
0.009 nA/μM (n=4).  The glucose sensor is employed to measure tear glucose levels in 
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anesthetized rabbits over 8 h while also measuring the blood glucose values.  A strong 
correlation between tear and blood glucose levels is found, suggesting that 
electrochemical measurement of tear glucose concentrations is a potential substitute for 







1.1  Overview of Dissertation Research 
 
Biocompatibility has been the major technical challenge in the development of 
implantable sensors capable of continuously monitoring blood glucose and lactate (See 
Fig. 1.1 for structures) for people afflicted with diabetes or critically patients in the 
Intensive Care Unit (ICU) of a hospital.  The intravenous thrombus formation and 
subcutaneous encapsulation by immune cells on the surfaces of implanted sensors greatly 
compromise the accuracy and reliability of such devices.  Nitric oxide (NO) is 
well-known as a potent anti-thrombus and anti-inflammatory agent that exists 
endogenously [1-5].  The work described in this thesis is focused on developing 
biocompatible coatings for implantable glucose/lactate sensors with NO 
release/generation, based on the hypothesis that NO released/generated on the surfaces of 
implanted devices will reduce intravascular thrombus formation and subcutaneous 
inflammatory response.  A newly developed glucose sensor intended for detecting 
glucose levels in tear fluid as a potential non-invasive way to monitor blood glucose will 





Figure 1.1.  Structures of (a) glucose and (b) lactate. 
 
This introductory chapter will discuss the importance of continuous monitoring of 
glucose/lactate and the current status regarding the development of implantable sensors 
with specific focus on the challenge of achieving biocompatibility.  Then, the 
incorporation of NO release/generation into sensor coatings will be introduced, 
specifically in the case of a poly(lactide-co-glycolide) (PLGA) matrix.  Lastly, the 
driving force behind the tear glucose measurement will also be discussed.    
 
1.2  Increasing Need of Continuous Glucose/Lactate Monitoring for Diabetic and 
Critically-Ill Patients 
 
According to the statistics from the World Diabetes Foundation, there are more 
than 285 million people currently diagnosed with diabetes in the world and the number is 
increasing every year [6].  For the past few decades, the dominant method for 
monitoring blood glucose, whether at home or in the hospital environment, has been 
intermittent measurement of capillary blood glucose, usually coupled with finger pricking.  
However, such measurements only provide isolated single-time point measurements that 




been great progress in the development of subcutaneous implantable electrochemical 
glucose sensors that provide real-time monitoring capability [7], there remain some issues 
regarding the lag time in response between changes in blood glucose levels and 
subcutaneous fluid concentrations, and requirements for frequent recalibration with blood 
levels.  For critically ill hospital patients, in particular, there is growing evidence that 
tight control of blood glucose levels can be of benefit not only to diabetic patients, but 
also to non-diabetics [8-12].  In this environment, intravenous sensor placement would 
be the preferred mode to gain the most accurate assessment of real-time blood glucose 
levels.  
 
Beyond glucose, the accurate monitoring of blood lactate levels is also of great 
biomedical importance in the critical care setting.  Lactate plays a vital role in several 
biochemical processes that are involved in muscle movement, and it is the key metabolite 
of the anaerobic glycolytic pathway.  In fact, blood lactate levels are now considered 
one of the most important indicators of the status of critically ill patients, with 
continuously elevated levels considered a key prognosticator of a poor outcome.  Hence, 
for such patients, the ability to monitor lactate continuously via an intravenous catheter at 
the patient’s bedside would provide a means to assess whether prescribed clinical 









1.3  Current Development of Implantable Glucose/Lactate Sensors and the 
Biocompatibility Problem 
 
A number of miniaturized electrochemical blood glucose and lactate sensors have 
been reported in the literature [19-21].  Figure 1.2 shows a common schematic of both 
glucose and lactate sensor designs and the mechanism of the corresponding substrate 
measurements.  The sensor is composed of a needle-type platinum/iridium (Pt/Ir) wire 
and wrapped with a silver/silver chloride (Ag/AgCl) reference electrode with 
glucose/lactate oxidase immobilized on the sensing area.  An inner layer of polymers is 
deposited on the surface of the working electrode at the sensing area to eliminate 
potential interferences within the biological sample.  An outer layer of polyurethane 
(PU)/polydimethylsiloxane (PDMS) is coated on the whole sensor in order to protect the 
implanted sensor.  This layer also functions to limit the glucose/lactate diffusion rate, to 
prevent a lower concentration of oxygen (O2) than the analyte in the enzymatic layer (that 
would yield non-linear response), so that the overall process is controlled by the diffusion 
of glucose/lactate rather than the pO2 tension.  Glucose/lactate diffuses into the enzyme 
layer and hydrogen peroxide (H2O2) is liberated from these enzymatic reactions with 
subsequent oxidation of H2O2 at the underlying electrode surface.  The resulting anodic 
current is proportional to the concentration of glucose or lactate in the sample.  Several 
commercial continuous glucose monitoring (CGM) systems based on subcutaneous 
devices have been developed for diabetic patients [22] (Fig. 1.3 (b)).  Girardin et al. 
recently reviewed both the biochemical perspectives and clinical applications of these 




Figure 1.2.  Schematic and the amperometric detection mechanism of glucose/lactate 
sensors. 
 
However, the development of intravenous sensors that can function reliably for 
extended periods after implantation remains technologically challenging largely due to 
the biocompatibility issues that arise.  When the sensor is implanted in the blood stream, 
especially within a readily available vein, thrombus formation can occur within minutes, 
triggered by platelet activation, adhesion and fibrin entanglement with blood cells (Fig 
1.3 (a)) [24].  Similarly, implanted devices designed for subcutaneous measurements are 
also subject to biocompatibility issues, such as an inflammatory response that leads to a 
fibrotic encapsulation of the devices within a sheath of leukocytes, macrophages, 
fibroblasts, etc. (Fig 1.3 (b)) [22].  Both situations disturb the physiological environment 
of the implantation site and may lead to false values of local glucose or lactate 
concentrations and/or decrease mass transfer of the analyte to the immobilized enzyme 
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layer of the device.  Either case can result in an unreliable analytical output which limits 
the lifetime and wide clinical use of such implantable sensors [25].  
 
 
         (a)                                 (b) 
Figure 1.3.  (a) Thrombus formation on the surface of intravenous sensor and (b) 
immune cell encapsulation of subcutaneous sensor from a commercial CGM system [22]. 
 
1.4  Implantable Sensors with NO Release/Generation Polymeric Coatings 
 
To overcome the hurdles discussed above, many researchers have focused on 
developing more biocompatible polymers for biomedical sensor applications.  Several 
proposed approaches include the use of hydrogels, surfactants and other surface-bound 
species in the effort to minimize sensor biofouling [26-28].  Because protein adsorption 
is the first step in the eventual formation of thrombus on the surface of intravascular 
sensors, decreasing protein adsorption should improve blood compatibility.  
Unfortunately, none of the approaches that are intended to prevent protein adsorption 
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completely eliminate thrombus in low flow blood vessels or fully prevent subcutaneous 
inflammatory responses when tested in vivo [24].   
 
The discovery of the anti-platelet and anti-inflammatory properties of NO has 
provided a new direction for research aimed at solving the fundamental biocompatibility 
problem of implanted sensors, as well as other blood contacting medical devices [2-5, 
29-39].  Indeed, NO is well-known as a potent inhibitor of platelet function [1, 40].  In 
fact, NO is produced within endothelial cells (ECs) that line the walls of all healthy blood 
vessels, and serves to prevent clotting by inhibiting platelet activation.  This led to the 
idea of coating intravascular-implanted sensors with polymers that can release or 
generate NO at physiological concentrations so that adhesion of cells (platelets) and 
concomitant thrombus formation at the surface of the sensor can be reduced (Fig. 1.4) 
[32].  Further, NO also inhibits the inflammatory response (reduces neutrophil and 
macrophage migration to the implant site), and promotes angiogenesis (growth of new 
blood vessels) [3-5].  These are both important effects that could greatly improve the 





Figure 1.4.  Concept of NO release/generation coatings on the surface of sensors 
implanted in blood to prevent thrombus formation and subcutaneously to reduce 
inflammation. 
 
Intravascular oxygen sensors with NO release incorporated into silicone rubber 
coatings have been successfully fabricated as previously reported [33, 41].  Those 
sensors were implanted in swine arteries for 20 h and the ones with NO release exhibited 
enhanced hemocompatibility with much less thrombus formation on the sensor surfaces, 
while the control ones without any NO release formed obvious thrombus.  The sensors 
with NO release also showed improved accuracy in reporting the blood oxygen levels, 
while the thrombus on the control sensor surfaces influenced the local oxygen 
concentrations near the sensing area, leading to the deviation from the bulk blood oxygen 
levels.  Intravascular oxygen sensors with NO catalytically generated from endogenous 
S-nitrosothiols (RSNOs) have also been proposed and the in vivo experiment data showed 
similar enhanced hemocompatibility and excellent analytical accuracy of the sensors with 
NO generation compared to the control ones [36].  As a result, it is promising to 
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incorporate NO release/generation into implantable glucose/lactate sensors to realize 
anticipated biocompatibility.   
 
1.4.1  NO Release Coatings Using Poly(lactide-co-glycolide) (PLGA) 
 
Herein, we report results of efforts in this direction that make use of a newly 
formulated NO release coating that consists of a lipophilic diazeniumdiolate species 
(N-diazeniumdiolated dibutylhexanediamine, DBHD/N2O2) embedded within a layer of 
poly(lactide-co-glycolide) (PLGA), which is then covered by an outer layer of PurSil 
(polyurethane/dimethylsiloxane copolymer).  DBHD/N2O2 readily releases NO upon 
contact with water by a proton driven mechanism [42] (Fig. 1.5).  PLGA undergoes a 
slow hydrolysis process to generate lactic acid and glycolic acid [43] (Fig. 1.6).  
Therefore, the use of PLGA as a matrix for the diazeniumdiolate NO donor provides an 
added source of protons to promote extended NO release, without the need for using 
tetraphenylborate derivative additives as described in previous work [42], the presence of 
which was found herein to inhibit enzymatic activity of both glucose and lactate oxidases.  
 
 






Figure 1.6.  Hydrolysis of PLGA to form lactic acid and glycolic acid. 
 
1.4.2  NO Generating Coatings 
 
On the other hand, the NO release application on implantable sensors has its 
limits as the reservoir of the NO donor will be depleted over time.  The 
diazeniumdiolates-doped PLGA matrix layer used to prepare glucose or lactate enzyme 
electrodes is typically rather thin (~30 μm from Fig. 3.4 in Chapter 3), thus the lifetime of 
NO release that can be achieved is limited by the amount of the NO donor loaded within 
the polymer coating.  The thickness of the coating cannot be further increased, because 
this would greatly influence the glucose/lactate diffusion which will impact the sensor 
performance (e.g., reduce sensitivity, slow response times, etc.).   
 
S-Nitrosothiols (RSNOs) are another class of NO donor species which are 
constantly produced in the body as a replenishing NO reservoir.  They have been proven 
useful for developing polymeric coatings that release or generate low levels of NO [44, 
45].  One mechanism to generate NO from RSNOs is via catalytic reactions with either 
Cu(II) [46] or organoselenium (RSe) species [47].  Hence, an attractive alternative to 
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using NO release polymers to make implantable sensors more biocompatible is to utilize 
polymeric coatings that can catalytically generate NO, locally at the surface of the 
implanted device, from the reservoir of RSNOs that already exists within blood.  Figure 
1.7 illustrates the concept of how polymeric coatings doped with immobilized Cu(II) 
complexes or RSe sites coated on catheter type sensors will generate NO locally from 
endogenous RSNO species in blood. 
   
 
Figure 1.7.  NO generating coatings with Cu/Se catalytic sites to generate NO from 
endogenous RSNO species. 
 
Some important physiological RSNOs are S-nitrosoglutathione (GSNO) (Fig. 1.8 
(a)), S-nitrosocysteine (CysNO) (Fig. 1.8 (b)) and S-nitrosoalbumin (AlbSNO) (Fig. 1.8 
(c)).  The estimated level of the primary endogenous RSNOs present in blood plasma is 
a subject of great debate, ranging from 10 nM to 7 µM [48].  However, recent studies in 
our lab using newly developed RSNO sensors suggest that levels in the µM range are 
likely, based on rapid measurements in whole blood of rabbits and pigs [49].  As a result, 
it is likely that there are enough endogenous RSNO species in blood to generate 
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physiological levels of NO from NO generating polymeric coatings.  For subcutaneous 
applications, research is still needed to determine the RSNO levels in subcutaneous fluid.   
 
     
                  (a)                                  (b) 
 
(c) 
Figure 1.8.  Structures of (a) GSNO, (b) CysNO and (c) AlbSNO (NO at Cys34). 
 
In the case of Cu(II) mediated generation of NO, Cu(II) is first reduced to Cu(I) 
by an appropriate free thiol (RSH), such as cysteine (Cys) or glutathione (GSH), as well 
as ascorbate in blood or even extracellular fluid (eq 1.1).  Then, Cu(I) readily reduces 
RSNO to NO and RSH [50, 51] (eq 1.2).  Recent research in this group has 
demonstrated that this catalytic mechanism can be incorporated into polymers using 
immobilized Cu(II)-ligand complexes as catalytic sites [52-54], or small microparticles of 
Cu
o
 that can corrode to produce trace levels of Cu(II/I) ions that can then react with 
RSNOs to generate NO [36].  Local reduction of RSNOs to NO and thiolate anions will 
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provide the further reducing equivalents to assist in regenerating the Cu(I) sites.  The 
Cu
0
 strategy was used previously to examine the performance of catheter type 
electrochemical oxygen sensors implanted in arteries of pigs for up to 20 h, and the 
sensors that possess copper coatings (doped with Cu
0
 nanoparticles) exhibited enhanced 
biocompatibility in terms of reduced thrombus, as well as improved analytical 
performance of accurately reporting blood oxygen levels [36].  It is potentially feasible 
to coat implantable glucose and lactate sensors with polymeric films containing Cu 
catalysts to generate NO from endogenous RSNO species for extended time periods when 





Another catalytic pathway that can be used to generate NO in vivo is via RSe 
species.  Previously, it has been demonstrated that NO generation from various RSNO 
species can occur catalytically using covalently linked diselenide species (RSe-SeR) to 
polymers such as cellulose filter paper and polyethylenimine (PEI) [47, 55].  Such 
RSe-derivatized polymers generate NO from RSNO species in the presence of an 
appropriate thiol reducing agent (e.g., GSH) (eq 1.3 - 1.5).  Recently, a new generic and 
easy approach to incorporate NO generation on almost any surface has been reported [56].  
Such NO generating coatings are created via a layer-by-layer (LbL) deposition process in 
which diselenodiproprionic acid (SeDPA) is covalently linked to PEI creating a 
polycationic polymer with Se sites that can catalytically liberate NO from RSNOs [56].  
14 
 
It has been found that 100 bilayers of the SePEI and alginate (Alg) as the counter 
polyanion yields 10 µm thick coatings on almost any substrate, with NO flux levels of ≥
1×10-10 mol cm-2 min-1 in the presence of 1 µM of RSNO substrate, the concentration 
likely present in fresh whole blood.  It is therefore potentially possible to use this LbL 
approach to create NO generating coatings on needle-type glucose and lactate sensors to 






1.5  NO Detection Method Using NO Analyzer (NOA) 
 
Continuous monitoring of released/generated NO flux directly from a device 
coating surface is feasible by direct measurement of NO using a chemiluminescence NO 
analyzer (NOA).  This method has very low detection limit (ppb NO) and excellent 
temporal resolution (seconds).  Indeed, NO reacts with ozone (O3) to generate excited 
state nitrogen dioxide (NO2*) which then relaxes to the ground state with the emission of 
light in the red and infrared region (~640 – 3000 nm) (eq 1.6 and 1.7).  A 









Figure 1.9 illustrates the NOA experimental setup.  Basically, the NO produced 
within a test solution in which the coated device (e.g., sensor) is placed is purged into the 
NOA reaction chamber by bubbling with nitrogen (N2) carrier gas.  The output signal is 







 by integrating the ppb/ppm signals, which is used as the standard NO 
surface flux unit in this dissertation. 
 
 
Figure 1.9.  NOA setup for detection of NO released/generated from coated devices in 








1.6  Tear Glucose Measurement as a Potential Non-Invasive Substitute for Blood 
Glucose Measurement 
 
As tight glycemic control is critical to the medical care of diabetic patients as well 
as to prevent complications such as cardiovascular disease [57],  it is often 
recommended that blood glucose levels be measured several times a day, which usually 
requires finger pricking coupled with measurement using a strip-test type glucometer.  
However, in practice, patients may not follow these recommendations, and this might be 
largely due to the accumulated pain from the repeated finger pricks and blood collection. 
 
Studies have been carried out to find a less invasive means to monitor blood 
glucose levels including infrared spectroscopy and fluorescence [58], a GlucoWatch 
design that uses the electro-osmotic flow of subcutaneous fluid to the surface of the skin 
and detection of glucose in the fluid by e-chem sensor [59], and measurement of tissue 
metabolic heat conformation [60].  Testing glucose concentrations in tear fluid has also 
been suggested [61].  If and when a close correlation between tear and blood glucose 
levels can be clearly shown, the tear glucose testing approach would provide a unique 
possibility of developing a relatively simple non-invasive method of detecting glucose 
concentration.  In this thesis work, a novel needle-type amperometric tear glucose 







1.7  Statement of Dissertation Research 
 
The purpose of the research described in this dissertation is to develop 
biocompatible coatings for implantable glucose/lactate sensors with NO 
release/generation.  A new polymeric matrix of PLGA to sustain long-term NO release 
is proposed and optimized.  Different NO generating coatings are also applied onto 
sensors to study the compatibility between NO generation and the sensing chemistry.  A 
novel tear glucose sensor is also examined as a potential substitute to traditional invasive 
ways to monitor blood glucose levels.         
 
Chapter 2 describes the development of the new NO release system using a PLGA 
matrix.  Different types of PLGA are studied to find the optimal one to sustain a 
prolonged NO release (when doped with appropriate NO donors) as well as to maintain a 
reasonable flux.  The optimal ratio of PLGA and NO donor is also established.  A 
prolonged NO release profile was found using PLGA as the polymer matrix.  To further 
understand the protein adsorption properties of such new NO release coatings, an in vitro 
fibrinogen adsorption immunofluorescence assay is carried out. 
 
Chapter 3 discusses the application of the new NO release polymeric coatings 
using PLGA on implantable glucose/lactate sensors.  The analytical performance of 
these devices is tested with NO release to compare with control sensors prepared without 
NO release.  Animal experiments are carried out to evaluate the anti-thrombotic 
properties of the NO release glucose sensor by implanting sensors into rabbit veins for 8 
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h.  The thrombus formation was observed after the sensors were explanted and the 
glucose sensor data are correlated to a standard in vitro glucose measurement in blood 
samples using a bench-top Radiometer instrument.  The work described in Chapters 2 
and 3 has been published as a full paper in Biosensors and Bioelectronics (2011) [62].  
 
Chapter 4 studies NO generating coatings for implantable glucose/lactate sensors.  
Cu(II)-cyclen polyurethane, polyurethane doped with Cu
0
 nanoparticles and Se-LbL are 
each used as the NO generating coating and the influence of NO generating chemistry on 
glucose/lactate sensing chemistry is examined.  Preliminary animal experiments using 
the Se-LbL coatings are also carried out to evaluate the anti-thrombotic properties of the 
SePEI/Alg coatings in the presence of physiological levels of RSNOs in the blood stream.    
 
Chapter 5 proposes a novel tear glucose measurement sensor with a capillary 
configuration.  The correlation between tear and blood glucose over an 8 h period is 
examined by using a rabbit model.  The feasibility of using tear glucose concentrations 
to predict blood glucose levels is also studied.  A US patent for this work has been filed 
and a full manuscript is to be submitted. 
 
Chapter 6 provides a summary of all the results and future directions of this 
dissertation work.  The use of sulfonated polyurethane as a potential NO release matrix 
is discussed.  Further development of biocompatible and biodegradable NO release 
polymeric coatings using RSNO in PLGA is also suggested.  In addition, the next 
generation of the tear glucose sensor is also previewed.  
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NITRIC OXIDE RELEASE USING A POLY(LACTIDE-CO-GLYCOLIDE) 
MATRIX 
 
2.1  Introduction 
 
As discussed in Chapter 1, considerable effort has been focused on developing 
more biocompatible materials for intravascular and subcutaneous sensors as well as other 
medical devices.  Nitric oxide (NO) has shown its potent inhibition to platelet activation 
and anti-inflammation functions.  In fact, the physiological NO flux from endothelial 







 [1].  Previous studies and initial results [2, 3] have shown promising 
biomedical application of NO release materials on implantable glucose sensors for 
improved biocompatibility in subcutaneous tissue, but the NO release lasted for only 1 to 
3 days.  The goal of research described in this chapter is to develop new polymeric 
coatings which prolong NO release to at least one week at physiologically relevant levels 
in order to realize enhanced biocompatibility and potential extended implantation times 




Initially, diazeniumdiolated dibutylhexanediamine (DBHD/N2O2) was doped as 
the NO donor in the outer polymeric PurSil (a copolymer of polyurethane and 
dimethylsiloxane, see Fig. 2.1 (a)) layer of the glucose sensor (see Fig. 1.2 in Chapter 1), 
similar to the approach reported previously for subcutaneous glucose sensor experiments 
[2].  Potassium tetrakis(4-chlorophenyl)borate (KTpClPB) (Fig. 2.1 (b)) was first used 
as a lipophilic counter ion to stabilize the pH level within the NO release polymers.  The 
increase in the basic environment, due to free amines produced after NO release, further 
slows the decomposition of the remaining diazeniumdiolates to release NO; however, as 
shown previously, the addition of the borate derivative helps buffer the organic phase, 
keeping the pH low [4] (via hydroxide and potassium ions diffusing out from the polymer 
matrix, with borate becoming the counteranion to the protonated amine of DBHD).  
Figure 2.1 (c) shows the difference in NO release profile with and without KTpClPB 
doped in the polymer with the same amount of DBHD/N2O2.  When the borate was 
added into the NO release polymer matrix, the released NO remained at a relatively 
steady flux, while without the borate the NO flux started to shut down within 30 min, due 
to the increased pH within the polymer preventing DBHD/N2O2 from further 












              (b)                                (c) 
Figure 2.1.  Structures of (a) PurSil and (b) KTpClPB.  (c) NO release comparison 
with and without the doped tetraphenylborate species.  
 
Unfortunately, when either glucose oxidase or lactate oxidase was in contact with 
the membrane containing the borate derivative for some time (days), both enzymes lost 
essentially all activity.  Control experiments were performed by fabricating glucose 
sensors that were coated with polymers containing only DBHD/N2O2, only borate or both 
borate and DBHD/N2O2.  Results showed that glucose sensors with only DBHD/N2O2 
maintained their catalytic activity, while the sensors with borate or with both species lost 
response to glucose.  This result suggests that the borate derivative, not the NO releasing 
diazeniumdiolate, deactivated the enzyme preventing the response of the glucose sensor 
when using outer NO release membranes containing these species.  The loss of enzyme 
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activity was possibly due to the generation of potentially toxic radical species from the 
cleavage of the carbon-boron bond during the proton-induced or oxidative degradation of 
the KTpClPB species [5].    
 
To overcome the borate deactivation effect on the enzyme activity, preliminary 
efforts to coat the sensors with an NO releasing PurSil layer, but excluding the sensing 
area where the enzymes are immobilized were undertaken.  It was hoped that the NO 
release from the surrounding area could prevent thrombus formation on this small 
opening.  However, an initial in vivo study showed that thrombus formation still 
occurred precisely on the 1-mm opening not covered by NO releasing material after 8 h 
of implantation in rabbit veins (Fig. 2.2).  As a result, a substitute for the borate, which 
can preserve the enzyme activity, was needed to prolong the NO release time while also 




Figure 2.2.  Preliminary in vivo study of NO release (excluding the sensing area) 
glucose sensor with borate (top) and control without NO release (bottom) explanted after 
8-hour implantation in rabbit veins.  Thrombus still formed on the sensing area of the 
NO release glucose sensor (top red circle).        
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Some other lipophilic anions were studied as substitutes for KTpClPB, including 
potassium tetrakis[3,5-bis-(trifluoromethyl)phenyl]borate, dinonylnaphthalene sulfonate 
(DNNS) and sodium cholate (Fig. 2.3).  However, they either deactivated the 
glucose/lactate oxidase as well, or did not help maintain a steady NO flux like KTpClPB 
does. 
 
             
           (a)                                (b) 
 
(c) 
Figure 2.3.  Structures of (a) potassium tetrakis[3,5-bis-(trifluoromethyl)phenyl]borate, 
(b) dinonylnaphthalene sulfonate (DNNS) and (c) sodium cholate. 
 
Poly(lactide-co-glycolide) (PLGA) is a widely used biodegradable and 
biocompatible copolymer which has been approved by the U.S. Food and Drug 
Administration (FDA) in numerous products, especially in drug delivery systems [6].  
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Further, PLGA is a candidate as a substitute for the toxic tetraphenylborate species to 
create an NO release coating because PLGA undergoes a slow hydrolysis to produce 
lactic acid and glycolic acid, and thus can provide an acidic micro-environment ideally 
suited for proton driven NO release from diazeniumdiolates [7-10].  As the PLGA is 
hydrolyzed, the lactic and glycolic acids can protonate the free amines produced in the 
NO release process from the DBHD/N2O2 species; thus long-term NO release can be 
ensured without influencing enzyme activity.  There are many types of PLGA with 
different hydrolysis speeds, controlled by the ratio of lactic and glycolic acid content, 
molecular weight and the end-cap type (free acid or ester-capped).  As a result, in this 
work different types of PLGA were examined, in order to prolong the sustained NO 
release at physiologically relevant levels.  The optimum PLGA was selected as the base 
material to create new NO releasing inner polymer coatings for both glucose and lactate 
sensors.  As hypothesized, PLGA did not have any negative influence on either the 
glucose or lactate oxidase activities which will be discussed in detail in Chapter 3. 
 
2.2  Experimental 
 
2.2.1  Materials 
 
N,N’-dibutyl-1,6-hexanediamine (DBHD), phenolphthalein, dinonylnaphthalene 
sulfonate (DNNS), sodium cholate, 1-(4-butylphenyl)-2,2,2-trifluoroethanone and 
poly(DL-lactide-co-glycolide) 50:50 (PLGA, RESOMER
®
 RG 502 H) were purchased 
from Sigma-Aldrich (St. Louis, MO).  Sodium chloride (NaCl), potassium chloride 
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(KCl), sodium phosphate dibasic (Na2HPO4), potassium phosphate monobasic (KH2PO4), 
potassium hydroxide (KOH), tetrahydrofuran (THF), dimethylacetamide (DMAc), 
methanol and acetone were from Fisher Scientific (Pittsburgh, PA).  PLGA 85:15, 
PLGA 50:50 (i.v. 0.60, ester terminated) and PLGA 50:50 (i.v. 0.19, ester terminated) 
were provided by Alkermes Inc. (Cambridge, MA).  Potassium 
tetrakis(4-chlorophenyl)borate (KTpClPB) and potassium 
tetrakis[3,5-bis-(trifluoromethyl)phenyl]borate were from Fluka (Ronkonkoma,NY).  
PurSil 20 80A was from the Polymer Technology Group (Berkeley, CA).  DBHD/N2O2 
was synthesized by treating DBHD with 80 psi NO gas purchased from Cryogenic Gases 
(Detroit, MI) at room temperature for 24 h, as previously described [4].   
 
2.2.2  Characterization of Different Types of PLGA 
 
NO release PLGA polymers were coated on IV polyurethane catheters (0.67 o.d. 
× 19 mm, Fisher Scientific, PA).  The catheters were first glued on the tip and dried 
overnight, then 10 µL of 5% (w/v) of 2:1 (w/w) PLGA and DBHD/N2O2 in THF were 
loop cast, covering 1.5 cm of the catheter, and finally coated with another 10 µL of ca. 4% 
(w/v) PurSil solution in 1:1.5 DMAc and THF.  The coated catheters were dried in air 
overnight and then vacuum dried for 1 day. 
 
PLGA 85:15, PLGA 50:50 (i.v. 0.60, ester terminated), PLGA 50:50 (i.v. 0.19, 
ester terminated) and PLGA 50:50 RG 502 H (i.v. 0.16-0.24, acid terminated) were 
examined as matrices containing DBHD/N2O2.  With the same amount (5 mg) of 
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DBHD/N2O2 incorporated, 10 mg of different types of PLGA were dispersed in 300 µL 
of THF and 10 µL was coated onto catheters as the NO release matrix and top-coated 
with 10 µL of ca. 4% (w/v) PurSil solution in 1:1.5 DMAc and THF.  The initial NO 
release was monitored by the NOA for 8 h.  As a control, the same amount of 
DBHD/N2O2 was also doped in PurSil but without PLGA.  The NO release profiles 
were compared and the optimal PLGA was chosen for future use.  
 
To optimize the ratio of DBHD/N2O2 and PLGA, 5 mg of DBHD/N2O2 was 
doped in 5, 10, 15 and 20 mg of PLGA 50:50 RG 502 H matrix and dispersed in 300 µL 
of THF.  Ten microliters of the suspension were coated onto the catheter and top-coated 
with PurSil.  The NO release was tested using the NOA for 8 h and the profiles of 
different NO donor to PLGA ratios were compared to determine the optimal ratio of 
diazeniumdiolate and PLGA to maintain a steady NO flux. 
 
Since NO release from DBHD/N2O2 is a proton driven mechanism, the residue 
acid number in different types of PLGA might also be influencing the initial NO release 
profile.  To determine the acid number, approximately 25 mg of the different PLGA 
types were dissolved in 5 mL of a 1:1 mixture of acetone and THF.  The solution was 
immediately titrated with 0.01 M KOH in methanol to a stable pink endpoint.  
Phenolphthalein methanol solution (0.1 wt%) was used as an indicator and 5 mL of 





2.2.3  Nitric Oxide Release In Vitro 
 
Nitric oxide released from coated catheters was monitored via chemiluminescence 
with a Sievers Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  The catheters were 
immersed into 0.1 M PBS, pH 7.4, at 37℃ and the NO flux data were collected.  
Long-term NO release was monitored over a 7-d period by collecting data for one hour 
each day.  The catheters were soaked in PBS at 37℃ with continuous nitrogen purging 
over this 7-d period to ensure that all sensors released NO under the same conditions as 
when measuring the NO flux using the NOA. 
 
2.2.4  In Vitro Fibrinogen Adsorption Immunofluorescence Assay 
 
To study the fibrinogen adsorption on to the NO release polymeric coatings, an in 
vitro fibrinogen adsorption immunofluorescence assay was carried out [11].  A 96-well 
microtiter plate (Nalge Nunc #437111, Rochester, NY) was coated with NO release and 
control polymers as shown in Figure 2.4.  Reconstituted solution was prepared by 
adding 100 mL of distilled water to each 4 g vial of Serotec BLOCK ACE (#BUF029, 
Raleigh, NC).  First, 1.5 mL of 44.4 mg/mL human fibrinogen (Calbiochem #341576, 
La Jolla, CA) was diluted with 22.2 mL Dulbecco’s phosphate-buffered saline (dPBS) to 
make a stock solution of 3 mg/mL.  Then, 100 µL of the 3 mg/mL fibrinogen solution 
was added to each polymer-containing microtiter well and incubated for 1.5 h at 37°C.  
The plate was washed 8 times using 100 µL of wash buffer each time (10-fold diluted 
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from reconstituted solution with 0.05% Tween 20 (Calbiochem, La Jolla, CA)) per well.  
To block nonspecific antibody binding, wells were incubated with 100 µL Blocking 
buffer (4-fold diluted from reconstituted solution) for 30 min at 37°C.  The plate was 
washed an additional 3 times using 100 µL wash buffer per well.  A background 
measurement of the plates was performed at 485/20 nm (excitation) and 528/20 nm 
(emission).  The purpose of pre-read blanks was to correct for well-to-well variability 
and to subtract the plate background (polymer-coated wells, with preadsorbed proteins) 
before measuring the fluorescence signals (polymer coated wells, with preadsorbed 
proteins and antibody).  To detect adsorbed fibrinogen, goat anti-human 
fibrinogen:FITC (MP Biochem #55169 CAPPEL, Solon, OH; 2ml DI water/vial) was 
diluted (1:10) in Diluent buffer (10-fold diluted reconstituted solution) and 100 µL was 
added to each well.  The antibody was allowed to bind to the surface-adsorbed 
fibrinogen for 1.5 h at 37°C.  Then the plate was washed 3 times using 100 µL of Wash 
buffer per well.  The measurements were performed with a fluorescence reader 
(Synergy 2, Biotek, Winooski, VT).  Human fibrinogen adsorption to non-coated 
polypropylene was used as an internal control to normalize the fluorescence signals of the 




Figure 2.4.  In vitro fibrinogen adsorption immunofluorescence assay plate 
configuration. 
 
2.3  Results and Discussion 
 
2.3.1  Comparison of Different Types of PLGA as the NO Release Matrix  
 
The various types of PLGA with different hydrolysis speeds may influence the 
NO release flux.  The higher the glycolide content in PLGA, the faster the hydrolysis 
rate, so PLGA 50:50 (lactide : glycolide) hydrolyzes faster than PLGA 85:15.  The 
molecular weight (in terms of the inherent viscosity (i.v., dL/g)) of the polymer also has 
an impact on the hydrolysis speed with a higher i.v. number yielding a slower hydrolysis 
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speed.  The polymer end-cap also plays a role in the hydrolysis speed, as the 
acid-terminated polymer chain hydrolyzes faster than the ester-terminated polymer.  As 
a result, PLGA 85:15, PLGA 50:50 (i.v. 0.60, ester-terminated), PLGA 50:50 (i.v. 0.19, 
ester-terminated) and PLGA 50:50 RG 502 H (i.v. 0.16-0.24, acid-terminated) were all 
used as the matrix of DBHD/N2O2 to release NO.   
 
Figure 2.5 shows the NO release profiles of different PLGAs and the control 
(without PLGA) for the first 8 hours, all with the same amount (5 mg) of DBHD/N2O2 
doped in 10 mg of the polymers.  All showed an initial burst of NO flux at around 30 
min after immersion in PBS buffer, and then gradually decreased to a steady NO flux.  
The burst of NO as well as the later steady NO flux follows the order (from the highest to 
lowest): PLGA 50:50 (i.v. 0.19) > PLGA 50:50 RG 502 H > PLGA 50:50 (i.v. 0.60) > 
PLGA 85:15.  It should be noted that all the polymers with PLGA have higher NO flux 
than the control (without PLGA), which indicates that PLGA does control the pH in the 
polymer matrix by providing a more acidic environment than the control of PurSil, 
resulting in higher NO flux.  The order of NO flux from different PLGAs appears to be 
consistent with the trend of a faster hydrolysis speed corresponding to a higher NO flux, 
except that PLGA 50:50 RG 502 H has the highest hydrolysis speed, but the NO flux is 
lower than that from PLGA 50:50 (i.v. 0.19).  To better understand these results, the 
residual acid numbers of the different types of PLGA were also measured and the results 
are shown in Table 2.1, combined with the NO flux at the highest burst.  From the 
titration results (n=3), PLGA 50:50 (i.v. 0.19) has a similar residual acid content to 
PLGA 50:50 RG 502 H, which cannot explain the higher NO burst flux than that from 
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PLGA 50:50 RG 502 H.  On a second thought, PLGA 50:50 RG 502 H is 
acid-terminated, so it is more hydrophilic and can be predicted to have a higher water 
uptake in the polymer matrix than PLGA 50:50 (i.v. 0.19) which is ester-terminated.  A 
higher water uptake reduces the acid activity in the PLGA matrix and results in a higher 
micro pH value [9], which in turns explains the lower initial NO burst from PLGA 50:50 
RG 502 H than PLGA 50:50 (i.v. 0.19).  As discussed above, PLGA 50:50 RG 502 H 
was chosen as the best PLGA for prolonged NO release, because it proved to sustain an 
NO flux at a reasonable range to potentially reduce thrombus formation.  Additionally, 
it had an initial NO flux that was lower than the PLGA 50:50 (i.v. 0.19), further 
preserving the NO donor reservoir. 
 
 




Table 2.1.  Residual acid number (n=3) and the corresponding NO flux at the burst peak 




(mg KOH/g PLGA) 
NO Flux Burst Peak 







50:50 RG 502 H 17.4 ± 1.1 21.5 
50:50 i.v. 0.19 18.1 ± 3.0 40.6 
50:50 i.v. 0.60 12.5 ± 0.4 9.4 
85:15 7.1 ± 0.6 6.0 
 
2.3.2  Optimization of the Ratio of NO Donor and PLGA Matrix 
 
In theory, to sustain a steady NO flux with added lipophilic anions to buffer the 
pH in the polymeric matrix, the molar ratio of doped anions and DBHD/N2O2 should be 
1:1.  However, as PLGA slowly hydrolyzes to produce the free acids to neutralize the 
amine groups, it is unknown if the hydrolysis speed will match the NO release process so 
that enough acid will be produced to maintain an acidic pH in the polymeric environment 
to prolong further NO release.  As a result, it was necessary to carry out experiments 
where the ratio of PLGA and DBHD/N2O2 was varied to determine the optimal amount 
of PLGA to sustain a steady NO flux. 
 
Figure 2.6 shows the NO release using different amounts of PLGA 50:50 RG 502 
H doped with the same amount (5 mg) of DBHD/N2O2.  It was found that when the 
amount of PLGA used was more than 10 mg, the steady NO flux did not change much.  
It was concluded that 5 mg of PLGA may not be enough to buffer the pH after NO is 
released from the 5 mg of DBHD/N2O2, so that the NO release process was slowed down 
resulting in a lower NO flux.  When the weight ratio of PLGA to DBHD/N2O2 is greater 
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than 2:1, the hydrolysis products are able to buffer the pH within the polymer matrix so 
that a steady NO flux can be maintained within the desired range.  It should be noted 
that for lactate sensors, more PLGA will result in a higher sensing background with more 
lactic acid produced locally, so the PLGA amount needs to be kept as low as possible 
while maintaining an acceptable NO flux.  As a result, a 2:1 ratio of PLGA and 
DBHD/N2O2 was chosen as the optimal polymer to NO donor ratio to prolong NO release 
for use with glucose/lactate sensors.                 
 
 
Figure 2.6.  NO release for coatings prepared with varying amounts of PLGA in 300 µL 






2.3.3  Prolonged NO Release Using PLGA 
 
Figure 2.7 shows the NO release of coated catheters over a one week period of 
time using PLGA as the matrix in which the DBHD/N2O2 is embedded.  The NO flux 






 approximately 30 min after 
immersion in PBS.  The NO release then decayed exponentially, but continued for more 






, which is similar to the NO flux produced 
by endothelial cells in cell cultures [1].  This NO release result is similar to that 
observed when using tetraphenylborate derivatives as an additive in the PurSil polymer 
matrix (Fig. 2.8).  On the other hand, with the same amount of DBHD/N2O2 alone 
doped into the PurSil polymer without the tetraphenylborate or PLGA, the maximum flux 













 within several hours (Fig. 2.8).  Hence, using a matrix that contained all 
PLGA for DBHD/N2O2 and a top coating of PurSil, provides a bilayer coating that 
releases NO for more than one week.  This is a much longer period than the previously 





Figure 2.7.  NO release of PLGA matrix doped with DBHD/N2O2 and top-coated with 
PurSil for more than one week.  
 
 
Figure 2.8.  NO release profile comparison of the same amount of DBHD/N2O2 in 
PLGA, PurSil with KTpClPB and PurSil only. 
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2.3.4  Fibrinogen Adsorption of NO Release Polymers 
 
Figure 2.9 shows the fibrinogen adsorption of NO release PLGA/PurSil polymer 
matrix as well as the control PLGA/PurSil polymer coatings compared to the 
polypropylene microtiter plate material.  It was found that both NO release and control 
PLGA/PurSil polymeric coatings adsorbed 20 times more fibrinogen than the 
polypropylene material.  The reason that the microtiter plate itself did not adsorb much 
protein may be due to the smooth surface of the wells from industrial production, while 
the coated polymers could potentially have rougher surfaces due to the hand-made 
process, which makes the polymers readily adsorb more proteins.  However, NO release 
coatings still showed excellent anti-thrombus functions from the animal experiments 
which are reported in detail in Chapter 3.  It was concluded that NO does not prevent 
protein adsorption on polymer surfaces, but the protein adsorption is not the key step in 
thrombus formation.  It is the platelet activation which ultimately triggers the thrombus 
formation and NO can downregulate the platelet activity.  As a result, NO release is 
crucial to prevent thrombus formation on polymeric surfaces when in contact with blood; 
the PLGA-based NO release coatings can be applied to multiple medical devices, 





Figure 2.9.  Fibrinogen adsorption results of the NO release coatings and control 
polymers on a microtiter plate. 
 
2.4  Conclusions 
 
Novel nitric oxide releasing coatings containing a lipophilic diazeniumdiolate NO 
donor species embedded in a PLGA matrix have been successfully developed that can 
release NO for more than one week at physiologically relevant levels.  PLGA 50:50 RG 
502 H was selected as the best PLGA to sustain the prolonged NO release at 
physiological levels for application on glucose and lactate sensors.  The 2:1 weight ratio 
of PLGA and DBHD/N2O2 was also chosen as the optimal polymer to NO donor ratio to 
realize the prolonged NO release.  Although the new NO release coatings tend to adsorb 
proteins on the surface, it can be anticipated that the released NO can still prevent 
thrombus formation by deactivating platelets, which is further described in Chapter 3.  
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The new NO release coatings using PLGA have prospective applications as coatings for 
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INTRAVASCULAR GLUCOSE/LACTATE SENSORS WITH  
NITRIC OXIDE RELEASE COATINGS 
 
3.1  Introduction 
 
As discussed in Chapter 1, it is desirable to develop intravenous glucose sensors 
to accurately monitor real-time blood glucose levels for critically ill hospital patients in 
order to decrease the potential complications for diabetic patients, as well as to gain 
better outcomes for non-diabetics, both benefitting from tight glycemic control [1-5].  
Beyond glucose, it is also important to continuously monitor blood lactate levels, as 
lactate is one of the most important indicators of survival for critically ill patients [6-11].  
Miniaturized implantable glucose and lactate sensors have been developed, but they still 
face the challenge of biocompatibility which might impair their reliability and extended 
usage after implantation [12, 13]. 
 
To enhance the biocompatibility of such implantable glucose/lactate sensors, it 
has been proposed to coat these devices with polymers capable of releasing or generating 
nitric oxide (NO), based on the fact that NO is a potent anti-thrombus and 
anti-inflammatory agent [14, 15].  Recent research in this laboratory [15-20] and 
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 of NO at the polymer/blood interface can effectively decrease the platelet 
adhesion and thrombus formation on the surfaces of implanted devices.  Further, 
working in collaboration with Dr. George Wilson’s group at the University of Kansas, 
our laboratory demonstrated that electrochemical glucose sensors prepared with NO 
releasing outer polymeric membranes greatly decreased the in vivo inflammatory 
response after subcutaneous implantation of sensors in rats for 2 days (when compared to 
control sensors implanted in the same animals), without degrading the analytical 
performance of the glucose sensor itself [25].  Schoenfisch and coworkers also modified 
miniaturized electrochemical glucose sensors with NO releasing xerogels and observed 
an improvement in biocompatibility over a 3 day period by analyzing the platelet and cell 
adhesion using in vitro assays [23].  To date, there are no reports on the use of NO 
releasing glucose sensors for making improved intravascular measurements, or the 
adaptation of this concept for preparing lactate sensors with improved in vivo 
biocompatibility.  In this chapter, a novel design for preparing intravascular glucose and 
lactate sensors with NO releasing polymeric coatings using the PLGA matrix described in 
detail in Chapter 2 is reported, and real-time in vivo data obtained for glucose sensing in 
the veins of rabbits confirms the reduced thrombus and improved analytical performance 






3.2  Experimental 
 
3.2.1  Materials 
 
Glucose oxidase (Type VII, From Aspergillus niger), d-(+)-glucose, 
glutaraldehyde, bovine serum albumin (BSA), iron (III) chloride (FeCl3), 37 % 
hydrochloric acid (HCl), cellulose acetate, methanol, L-lactate, L-ascorbic acid, uric acid, 
Nafion (5 wt % solution in a lower aliphatic alcohols/H2O mix), 1, 3-diaminobenzene, 
resorcinol, tetrahydrofuran (THF), dimethylacetamide (DMAc), 
N,N’-dibutyl-1,6-hexanediamine (DBHD), polyethylenimine (PEI) and 
poly(DL-lactide-co-glycolide) 50:50 (PLGA, RESOMER
®
 RG 502 H) were purchased 
from Sigma-Aldrich (St. Louis, MO).  Sodium chloride (NaCl), potassium chloride 
(KCl), sodium phosphate dibasic (Na2HPO4) and potassium phosphate monobasic 
(KH2PO4) were from Fisher Scientific (Pittsburgh, PA).  Platinum/iridium (Pt/Ir) and 
silver (Ag) wires were products of A-M Systems (Sequim, WA).  Lactate oxidase was 
obtained from Genzyme (Cambridge, MA).  Potassium tetrakis(4-chlorophenyl)borate 
(KTpClPB) was from Fluka (Ronkonkoma, NY).  PurSil 20 80A was from the Polymer 
Technology Group (Berkeley, CA).  DBHD/N2O2 was synthesized by treating DBHD 
with 80 psi NO gas purchased from Cryogenic Gases (Detroit, MI) at room temperature 






3.2.2  Fabrication of NO Release Glucose/Lactate Sensors 
 
The design of the needle-type glucose sensor was based on previous publications 
[25, 27].  Briefly, a 1-mm cavity was cut at 4 mm from one tip of a 10-cm-long 
Teflon-coated Pt/Ir wire of 0.2 mm outer diameter (see Fig. 3.1).  A 15-cm, 0.1-mm o.d. 
silver/silver chloride (Ag/AgCl) wire was tightly wrapped around the sensor starting 1.5 
mm above the opening covering a length of 4 mm.  The Ag/AgCl wire was prepared by 
dipping the Ag wire into a FeCl3/HCl solution.  The straight section above the wrapped 
Ag/AgCl wire was covered with a 5-cm long, 0.4-mm o.d., heat shrinkable polyester 
tubing (Advanced Polymers, Salem, NH).  The 1-mm opening of the sensor was 
dip-coated with a thin layer of Nafion.  Then, an in situ electropolymerization coating 
was applied using a Voltammograph potentiostat (Bioanalytical Systems Inc., W. 
Lafayette, IN) cycling voltage between 0 and +830 mV at 2 mV/s for 18 h with 
1,3-diaminobenzene and resorcinol [28] to enhance selectivity over interferences that are 
electroactive, e.g., ascorbate, urate, and acetaminophen.  One microliter of glucose 
oxidase solution with BSA was then dropped in the cavity along the wire.  This layer 
was dried for 30 min and then crosslinked by adding 1 µL of 2% (vol/vol) glutaraldehyde 
solution and allowing it to cure in air for 1 h.  The sensor was then rinsed with water, 
and allowed to dry for 1 h.  NO release sensors were first loop cast with 2:1 (wt/wt) 
PLGA and DBHD/N2O2 in THF and then ca. 4% (wt/vol) PurSil solution in 1:1.5 DMAc 
and THF.  Control sensors were first coated with PLGA solution in THF without the 





Figure 3.1.  Configuration of NO releasing glucose/lactate sensors. 
 
The fabrication of the lactate sensor was the same to that of the glucose sensor, 
except that the enzyme solution used was lactate oxidase stabilized with 0.7% of PEI, and 
the crosslinking time was 2 h instead of 1 h. 
 
3.2.3  Analytical Performance of NO Release Glucose/Lactate Sensors 
  
Glucose and lactate sensors were calibrated on a 4-channel potentiostat BioStat 
(ESA Biosciences Inc., Chelmsford, MA).  The sensors were tested at an applied 
potential of +600 mV vs. Ag/AgCl reference in 0.1 M phosphate buffer saline (PBS), pH 
7.4 at 37℃.  The buffer was purged with 10% oxygen in nitrogen (Cryogenic Gases, 
Detroit, MI) to ensure that the sensors can provide a linear response to 15 mM glucose 




The stability of NO release glucose/lactate sensors was tested by calibrating the 
sensors over one week and monitoring the sensitivity change.  The normalized 
sensitivity of NO releasing glucose/lactate sensors over one week period of time was 
plotted and the sensitivity percentage was calculated by dividing the sensitivity on each 
day by that on day 7.  To test the repeatability of the NO releasing glucose sensor, the 
devices were inserted into a 5 mM glucose solution 5 separate times, with washing and 
allowing the baseline to stabilize in between these multiple measurements.  The glucose 
concentrations were then back-calculated using the calibration curve plotted earlier and 
the average was taken to evaluate the repeatability of such sensors.   
 
To test the selectivity of NO release sensors over naturally existing interferences 
such as ascorbic acid, uric acid and other neutral molecules such as acetaminophen, the 
maximum possible in vivo level of interfering species were added into the solution when 
calibrating the sensors.  Using an NO release glucose sensor for an example, the % error 
was calculated by dividing the current from interferences (0.5 mM for ascorbic acid and 
0.2 mM for acetaminophen [29]) by the signal from 5 mM of glucose.  The selectivity 
was monitored for one week to test the stability of the inner polymeric layer for blocking 
those interferences. 
 
3.2.4  Nitric Oxide Release In Vitro 
 
Nitric oxide released from both glucose and lactate sensors was monitored via 
chemiluminescence with a Sievers Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  
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The sensors were immersed into 0.1 M PBS, pH 7.4, at 37℃ and the NO flux data were 
collected.  Long-term NO release was monitored over a 7-day period by collecting flux 
data for 1 h each day.  The sensors were continuously soaked in PBS at 37℃ with 
nitrogen purging to ensure that all sensors release NO under the same conditions as when 
measuring NO flux using the NOA. 
 
To measure the NO release coating thickness of the sensors, an NO release 
glucose sensor was cut in the sensing area and the Ag/AgCl reference electrode wrapped 
portion.  Images were taken at the cross-sections using a Scanning Electron Microscope 
(SEM, Hitachi S-3200N), and the coating thickness was estimated from these images. 
 
3.2.5  In Vivo Protocol for Evaluation of Both Sensor Performance and 
Biocompatibility 
 
A total of 15 white rabbits (Myrtle’s Rabbitry, Thompson’s Station, TN) were 
used in this study to test the glucose sensors only.  A protocol as described elsewhere in 
detail was followed for the in vivo experiments except with the maintenance fluid rate 
adjusted to 3.3 mL/kg/min [22].  One control (without NO release) and two NO release 
glucose sensors were implanted in the veins of an anesthetized rabbit for 8 h (Fig. 3.2).  
All the sensors fabricated for the in vivo study were first glued into 24-gauge IV 
polyurethane catheters (0.67 o.d. × 19 mm, Fisher Scientific, PA), and then coated with 
outer polymers (PurSil) (Fig. 3.2).  The electrochemical response of each sensor to 
blood glucose was monitored via the output current of the sensors.  To calibrate the 
sensors and evaluate the analytical performance regarding sensing glucose, 0.6 mL of 
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blood was drawn from the rabbits every 30 min to test the blood glucose level using a 
700 Series Radiometer blood analyzer (Radiometer America Inc., Westlake, OH).  The 
blood glucose level measured in vitro on the Radiometer instrument after 1 h of sensor 
implantation was used to set a one point calibration for each of the implanted sensors [30, 
31], and the continuous output thereafter was compared to the other intermittent blood 
glucose values.  After 8 h, the sensors were explanted and the thrombus formation on 
each device was documented via digital photography.  For a quantitative analysis of the 
thrombus formation, Image J software (http://rsbweb.nih.gov/ij/index.html) was used to 
measure the area of the red pixels (thrombus) from the photos, and the results of the 
control and NO release sensors were compared. 
 
 
Figure 3.2.  In vivo experimental configuration of glucose sensors implanted in rabbit 




3.3  Results and Discussion 
 
3.3.1  Prolonged NO Release of Glucose/Lactate Sensors 
 
Figure 3.3 shows the NO release of glucose/lactate sensors over a one week 
period of time using PLGA as the matrix in which the DBHD/N2O2 is embedded.  The 






 (n=4) approximately 
30 min after immersion in PBS.  The NO release then decayed exponentially, but 






, a flux similar to the 
NO flux produced by endothelial cells in cell cultures [32].  Hence, using a matrix that 
contained all PLGA for DBHD/N2O2 and a top coating of PurSil, provides a bilayer 
coating that releases NO for more than one week without influencing the enzyme activity.  
This is a much longer period than the previously proposed NO release glucose sensors 





Figure 3.3.  NO release of glucose/lactate sensors for over 7 days (n=4).   
 
Figure 3.4 shows the cross-sectional SEM images of the NO release glucose 
sensor at (a) the sensing area where the enzyme is immobilized and (b) the Ag/AgCl wire 
wrapped area.  It can be seen that both the inner PLGA/DBHD/N2O2 coatings and the 





     (a)                              (b) 
Figure 3.4.  SEM images of cross-sections of the NO release glucose sensor (a) at the 
sensing area and (b) at the Ag/AgCl wrapped area. 
 
3.3.2  In Vitro Performance of NO Release Glucose/Lactate Sensors  
 
In addition to biocompatibility, any enzyme-based sensor aimed at real biological 
applications must have reasonably stable sensitivity, a wide enough linear range for blood 
measurements, good response times and an acceptable selectivity over naturally existing 
interferences.  Figure 3.5 shows the typical current measurement of the NO release 
sensor for (a) glucose and (c) lactate, as well as the plotted calibration curve of the linear 
concentration range of (b) glucose and (d) lactate.  For glucose sensors, 0.5 mM of 
ascorbic acid, 0.2 mM of acetaminophen and aliquots of 5, 10 and 15 mM of glucose 
were added into the solution in the order as shown in the figure.  For lactate sensors, 





                   (a)                               (b) 
 
                   (c)                               (d) 
Figure 3.5.  Amperometric responses and corresponding calibration curves of NO 
release sensors for (a), (b) glucose and (c), (d) lactate.  For glucose sensor calibration in 
(a), 0.5 mM of ascorbic acid, 0.2 mM of acetaminophen and aliquots of 5, 10 and 15 mM 
of glucose were added into the solution in this order as shown in the figure.  For lactate 
sensor calibration in (b), aliquots of 2, 4 and 6 mM of lactate were used for the 
calibration. 
 
The in vitro normalized sensitivity of NO releasing glucose sensors (n=4) over a 
one week period of time is shown in Figure 3.6 (a).  The sensitivity percentage was 
calculated from dividing the sensitivity on each day by that on day 7.  As is shown in 
Fig. 3.6 (a), the sensitivity increased during the first 3 days because of the conditioning of 
the outer polymeric coatings (water uptake), and remained relatively stable thereafter.  
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The NO releasing glucose sensors showed a stable sensitivity from 1.9 to 3.7 nA/mM, 
had a linear range from 0 to over 15 mM under a 10% level of oxygen (pO2 of 70 mmHg) 
which is close to the venous blood oxygen levels, and the steady-state current was 
reached within 5 minutes.   
 
 
                    (a)                             (b) 
Figure 3.6.  Normalized sensitivity of (a) NO releasing glucose sensors (n=4) and (b) 
NO releasing lactate sensors (n=3) over one week period of time.  The percentage was 
calculated by dividing the sensitivity values on each day by the sensitivity on day 7. 
 
Figure 3.6 (b) shows the stability of NO release lactate sensors (n=3) over one 
week in terms of the normalized sensitivity.  The sensitivity decreased slightly over time, 
which is possibly due to the gradual loss in enzyme activity.  Indeed, lactate oxidase is 
known to be a less stable enzyme than glucose oxidase [34].  The NO releasing lactate 
sensors exhibited a stable sensitivity range from 4.9 to 7.2 nA/mM, had a linear range 
from 0 to 10 mM lactate and the response time was less than 2 minutes.  Both NO 
releasing glucose and lactate sensors showed acceptable in vitro analytical performance 
over a 7-day period, similar to the designs proposed earlier [27, 35], and were viewed as 
potentially useful for in vivo measurement. 
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The repeatability of the NO release glucose sensors was tested by inserting the 
device into 5 mM glucose solutions 5 separate times, with washing and allowing the 
baseline to stabilize in between these multiple measurements.  Figure 3.7 shows the 
results from the repeated measurements of 5 mM glucose.  The glucose concentrations 
were back-calculated using the calibration curve plotted earlier.  The sensor showed an 




Figure 3.7.  Repeat measurements of 5 mM of glucose from the NO release glucose 
sensor. 
 
When NO release was first introduced to create an implantable glucose sensor, 
there was some concern about an increase in the background current (due to oxidation of 
NO at the platinum anode) that could add inaccuracy to the glucose measurement, 
especially in the case of using a one-point calibration for the in vivo application.  From 









 had an average background current of 2.3±0.9 nA (n=4) which was 
only slightly higher than the control sensors without NO release, that had an average of 
1.2±0.7 nA (n=4).  However, NO releasing sensors had a sensitivity range from 1.9 to 
3.7 nA/mM, so the signal-to-background ratio at normal glucose levels (5.5 mM) was 
between 5 and 10.  Furthermore, the background current of NO releasing glucose 
sensors in the blood stream is expected to be lower than tested in vitro, as there are many 
biological NO scavengers, such as oxyhemoglobin that exist in the blood, that will 
decrease the flux of NO toward in the inner platinum working electrode of the 
intravascular sensor.  As a result, the background current contributed from NO release is 
negligible for intravascular applications, especially for the glucose sensor with 
sensitivity > 2 nA/mM.  The NO contribution to the lactate sensor background is greater 
than the glucose sensor because normal lactate levels can be < 0.5 mM.  Nevertheless, 
for real measurements, especially for patients in the ICU with elevated lactate levels > 2 
mM, the current from the NO background is < 20% of the signal that would occur at 
these levels of lactate.  Although undesirable, a two-point calibration can be performed 
when the sensor background from NO release is contributing significantly to the sensor 
signal.   
 
When PLGA was first applied to the NO releasing lactate sensor, there was a 
concern that the lactic acid produced would also increase the background signal.  
However, the results showed that the increase in background signal was from NO rather 
than lactate, as the background was similar to that of the NO releasing glucose sensor 
with the same level of NO release.  Indeed, the degradation timeframe of the PLGA 
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50:50 with an internal viscosity of 0.16 - 0.24 dL/g is known to be 2 - 4 weeks [36].  
Thus, the hydrolysis of the PLGA layer coated onto sensors under the PurSil layer occurs 
at a very slow rate producing very low steady-state levels of lactic acid (likely in the 
nanomolar range) in the sensing layer of the device, while the physiological levels of 
lactic acid are in the millimolar range.  As a result, PLGA is suitable to use to prolong 
NO release on lactate sensors without adding inaccuracy to the analytical performance.   
 
The NO release sensors also need to have excellent selectivity over naturally 
existing interferences such as ascorbic acid, uric acid and other neutral molecules such as 
acetaminophen, in order to be considered for real clinical application.  The 
electropolymerization of 1, 3-diaminobenzene and resorcinol was applied as the inner 
layer onto the sensing area with an underlying layer of Nafion [28, 37].  The monomers 
were electropolymerized at the electrode surface only in the pores of the Nafion layer 
which created a composite polymer mixture.  Figure 3.8 shows the structures of the 
monomers and the proposed electropolymerized polymer.  Figure 3.9 illustrates the 
cyclic voltammogram of the electropolymerization process.  The peak current dropped 
significantly after 18 h of reaction, indicating the formation of a non-conducting polymer 
layer on the sensing surface.  The selectivity results for NO releasing glucose sensors 
over major interferent molecules are shown in Table 3.1.  Using the NO releasing 
glucose sensor for an example, the % error was calculated by dividing the current from 
the maximum possible in vivo level of interferences (0.5 mM for ascorbic acid and 0.2 
mM for acetaminophen) by the signal from 5 mM of glucose.  Even though the 
selectivity decreased over a one-week period, the % error remained < 3% for ascorbic 
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acid and < 7% for acetaminophen.  This indicated that the sensor could retain a 




Figure 3.8.  Structures of 1,3-diaminobenzene, resorcinol and the corresponding 
electropolymerized polymers.   
 
 
Figure 3.9.  Cyclic voltammogram of the 18 h electropolymerization of 










Day 3 5 6 7 
Ascorbic acid (%) 0 1.10±1.01 2.08±1.09 2.88±1.53 
Acetaminophen (%) 1.86±1.38 3.31±1.09 5.35±1.66 6.76±1.67 
 
a
 Selectivity was measured by dividing the current from the maximum possible 
physiological level of interferences (0.5 mM for ascorbic acid and 0.2 mM for 
acetaminophen) by the signal from 5 mM of glucose. 
 
3.3.3  Blood-Compatibility and Surface Thrombus Evaluation of NO Release 
Glucose Sensors 
 
All the control and NO release glucose sensors were conditioned in PBS buffer 
for 3 days before implantation in rabbit veins to ensure stable sensitivity during the in 
vivo experiments.  For NO releasing sensors, the NO flux was checked by the NOA both 
before and after the in vivo implantation, and the NO flux results were similar to the in 
vitro NO release profile, as shown in Figure 3.3.  Figure 3.10 shows the NO release flux 
measurements of 2 individual NO release glucose sensors (a), (c) before and (b), (d) after 
the 8 h implantation in rabbit veins.  From Figure 3.10, it can be seen that the NO 












                (a)                                 (b) 
 
                (c)                                 (d) 
Figure 3.10.  NO release of 2 individual glucose sensors (a), (c) before and (b), (d) after 
8 h of implantation in rabbit veins.  
 
Figure 3.11 (a) and (b) shows photos of control and NO releasing glucose sensors 
explanted from rabbit veins after 8 h of implantation.  The results from two individual 
rabbit experiments with three sensors implanted in each were shown in photos (a) and (b).  
As can be seen from the photos, the bottom two NO releasing sensors in both (a) and (b) 
showed minimal thrombus formation on the surface, while the one control sensor (top) 
without NO release formed obvious thrombus on the surface.  The copolymer of 
polyurethane and siloxane, PurSil, with a blank underlying PLGA layer, is clearly 





(a)                               (b) 
Figure 3.11.  Glucose sensors explanted after 8-h implantation in rabbit veins.  Photos 
(a) and (b) demonstrate the drastic difference in thrombus formation between control (top) 
and NO releasing (middle, bottom) glucose sensors in two example rabbits.   
 
Using the Image J software, a more detailed statistical analysis of thrombus 
formation was performed.  Figure 3.12 shows an example of extracting the red pixel 
area from the original picture using Image J.  Then the red pixel area was measured 
indicating the amount of thrombus formed on sensor surfaces.  From the picture, the red 
area of the control glucose sensor reads 0.357 cm
2
 while the two NO release glucose 
sensors read 0.083 and 0.253 cm
2
, respectively.  NO release sensors formed much less 





Figure 3.12.  Measurement of the red pixel area of explanted sensors using Image J.  
 
Figure 3.13 shows the comparison of the overall thrombus formation between NO 
releasing (n=30) and control glucose sensors (n=15) in the 15 rabbits used for the in vivo 
testing experiments.  Although the deviations were comparatively large, the mean 
values are statistically different, with NO releasing glucose sensors forming considerably 
less thrombus than control sensors without NO release (p<<0.05).  These results 
confirm the expected anti-thrombus function of NO emission from the surface of the 











Figure 3.13.  Red pixel area in terms of thrombus formation of both control (n=15) and 
NO releasing glucose sensors (n=30). 
 
It should be noted that from the protein adsorption results in Chapter 2, the NO 
release coatings tend to adsorb a large amount of proteins such as fibrinogen on the 
surface.  However, from the in vivo results described above, the released NO still 
prevented thrombus formation by deactivating platelets.  As suggested in the literature 
[38], that platelet activation is the key step which ultimately triggers the thrombus 
formation in vivo and NO effectively downregulats platelet activity.  As a result, NO 
release is crucial to prevent thrombus formation on polymeric surfaces in contact with 
blood.   
 
3.3.4  In vivo Glucose Sensor Performance 
 
The implanted NO releasing and control glucose sensors were calibrated by a 
bench top commercial Radiometer instrument (blood-gas/electrolyte/metabolite analyzer) 
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using a one-point calibration method described earlier.  The calculated blood glucose 
values of the implanted glucose sensors were also correlated to the Radiometer readings.  
There was a strong correlation between readings from the in vivo and in vitro devices, 
with the correlation coefficient between the glucose readings from the sensors and that 
from the Radiometer being 0.7742 (p<<0.05) (n=30) for 15 separate in vivo sensor 
experiments. 
 
Figure 3.14 shows an example of the 8 h continuous monitoring of blood glucose 
levels reported by NO release and control glucose sensors as well as the bench-top 
Radiometer instrument.  It can be seen that the values from both NO release glucose 
sensors matched with that from the in vitro measurements, while the control glucose 
sensor showed a deviation starting at around 2 h after implantation.  This could be due 
to the fact that local glucose diffusion was disturbed by the thrombus formation on the 
implanted control sensor surface, leading to a false current output for a given level of 
glucose in the blood stream.  This result correlated to the thrombus formation results 
shown in Figure 3.11, that the glucose output readings were reliable when the surfaces of 
NO release glucose sensors are clean, while the reported blood glucose results showed 
deviation from the real blood glucose concentrations when the control sensor formed 
thrombus on the surface.    




Figure 3.14.  Continuous glucose monitoring results from implanted NO releasing and 
control sensors with comparison to the bench-top Radiometer readings. 
 
To evaluate the accuracy of both NO release and control glucose sensors from a 
statistical view, the Clarke error grid analysis method was carried out [39].  The x axis 
(reference concentration) shows the control blood glucose readings from the bench-top 
Radiometer and the y axis shows the concentration readings from the implanted sensors.  
From the Clarke error grid shown in Figure 3.15, the NO releasing glucose sensors 
exhibited more accurate detection of glucose in the blood stream than the control sensors.  
Nitric oxide releasing sensors had 97.5% of data points in Zone A (clinically accurate 
zone) and Zone B (benign error zone with no clinical consequences) (Fig. 3.15 (a)), 
where measurement results are accepted as accurate, while control sensors had 86.7% of 
data points in these zones (Fig. 3.15 (b)).  This is likely due to the fact that the thrombus 
formation on the implanted control sensors disturbed local glucose diffusion, leading to 
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false current output for a given level of glucose in the blood stream.  Indeed, control 
sensors had significantly more data points in the upper zone C (leading to unnecessary 
treatment) than NO release sensors.  This was likely due to the one-point calibration 
after 1 h of implantation when control sensors might already have developed thrombus on 
their surfaces which lowered the sensors’ apparent sensitivity, thus leading to higher 
blood glucose readings during the first hour of implantation.  The NO releasing sensors 
remained relatively accurate in reporting blood glucose levels as a result of NO 
down-regulating the platelet activity, thus eliminating thrombus formation.  Furthermore, 
the thrombus formed on the surface of the implanted control devices could block blood 
flow within the vessel, which would have a negative effect on the local implant site, and 
ultimately be dangerous for the patient.   
 
 
  (a)                                (b) 
Figure 3.15.  Comparison of glucose measurement results for (a) control (n=15) and (b) 
NO releasing glucose sensors (n=30) when implanted in rabbit veins for 8 h using the 




3.4  Conclusions 
 
Nitric oxide releasing glucose and lactate sensing catheters have been successfully 
fabricated that exhibit NO release for more than one week at levels that attenuate 
thrombus formation using a new PLGA-based coating containing a lipophilic 
diazeniumdiolate NO donor species.  The analytical performance of both the glucose 
and lactate sensors is not influenced significantly by the NO release or PLGA 
degradation products.  The sensors exhibit relatively stable amperometric response over 
a one-week period with high selectivity over interferences, making them suitable for 
blood monitoring applications.  An in vivo study (intravenous) of glucose sensors 
prepared in this manner showed that this coating exhibits a very good anti-thrombotic 
property for the implanted sensors, while not disturbing the glucose sensing function.  
Nitric oxide releasing glucose sensors implanted in the veins of rabbits for 8 h showed 
greatly reduced thrombus formation on their surfaces compared to corresponding controls.  
Further, improved accuracy in reporting blood glucose levels of NO release glucose 
sensors is achieved vs. controls as evaluated using a Clarke error grid type analysis.  
Although the lactate sensor reported here has not yet been evaluated for in vivo 
performance, the data on this sensor reported herein marks the first time that a lactate 
sensor has been formulated with an NO release coating.  Thus, the data presented in this 
chapter for the lactate sensor demonstrates that NO release chemistry does not interfere 
with the lactate oxidase chemistry.  While used here only for preparing glucose and 
lactate catheter style electrochemical sensors, the new NO release coating using PLGA 
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has prospective applications as a coating for many other blood-contacting biomedical 
devices.    
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IMPLANTABLE GLUCOSE/LACTATE SENSORS WITH NITRIC OXIDE 
GENERATION COATINGS 
 
4.1  Introduction 
 
As discussed in Chapter 1, the lifetime of the NO release method is limited by the 
amount of NO donors (diazeniumdiolates) doped within the polymer matrix, which 
cannot be increased without a limit in the function of the implantable sensor.  To take 
the advantage of the perpetual reservoir of endogenous RSNOs in blood, there is interest 
in the method of catalytically generating NO from such RSNO species as an alternative to 
the NO release method in order to further prolong the effective NO release time frame. 
 
Copper(II) is reported as the most efficient metal ion catalyst in generating NO 
from RSNOs [1].  Recent research in this group has successfully incorporated this 
catalytic mechanism into synthesized polymers, including polyurethane (PU) that 
possesses covalently immobilized Cu(II)-ligand complexes as catalytic sites [2-4].  It 
has also been demonstrated that micro and nano particles of Cu
o 
that naturally corrode to 
produce trace levels of Cu(II/I) ions can also generate NO via endogenous RSNOs [5].  





nanoparticle-doped polyurethane as the outer coatings for implantable glucose/lactate 
sensors is demonstrated.  The Cu(II) sites within the polymers can catalytically generate 
NO in situ from RSNOs existing in the blood stream or subcutaneous fluids and 
potentially enhance the biocompatibility of such implantable devices.  
 
 
Figure 4.1.  Structure of Cu(II)-cyclen-PU.  TPU = Tecophilic SP-93A-100 or 
Tecophilic SP-60D-60 polyurethanes. 
 
Beyond Cu(II), organoselenium (RSe) species have also been shown to be 
catalysts for generating NO from RSNOs [6].  While the synthesis of PU materials with 
covalently linked RSe sites intended for the use as the outer coatings for glucose/lactate 
sensors can be complicated, our lab has developed a generic and simple layer-by-layer 
(LbL) deposition approach to incorporate the RSe catalytic sites for NO generation on 
almost any surface, including PU [7].  Such LbL NO generating coatings are created 
from alternate layers of polycationic RSe-linked polyethyleneimine (SePEI) and 
polyanionic alginate (Alg).  Figure 4.2 shows the idea of depositing such LbL coatings 
onto implantable sensors with NO generation.  Enhanced biocompatibility of such 





Figure 4.2.  Schematic of an implantable sensor coated with SePEI/Alg via LbL 
deposition. 
 
Apart from the NO generation efficiency of the catalysts, the NO flux from the 
implantable device surface will also be dependent on the RSNO levels in the blood 
stream or within the subcutaneous fluid.  Thus the development of implantable glucose 
and lactate sensors using outer coatings with NO generation to improve biocompatibility 
is dependent on the levels of endogenous RSNO species.  However, much debate 
remains on the actual levels of endogenous RSNOs, ranging from as low as 10 nM to as 
high as 7 µM [8].  The research described in this chapter is aimed at exploring and 
optimizing the chemistries required for the fabrication of implantable amperometric 
glucose/lactate sensors with outer polymeric films that can slowly generate low levels of 
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NO from endogenous RSNO species that are present in the blood stream and likely 
present in the interstitial fluid. 
 
4.2  Experimental 
 
4.2.1  Materials 
 
Glucose oxidase (Type VII, From Aspergillus niger), d-(+)-glucose, 
glutaraldehyde, bovine serum albumin (BSA), iron (III) chloride (FeCl3), 37 % 
hydrochloric acid (HCl), sulfuric acid (H2SO4), sodium nitrite (NaNO2), reduced 
L-glutathione (GSH), L-lactate, L-ascorbic acid, uric acid, Nafion (5 wt % solution in 
lower aliphatic alcohols/H2O mix), 1,3-diaminobenzene, resorcinol, 
l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), sodium borohydride  (NaBH4), 
N-hydroxysuccinimide (NHS), 2-(N-morpholino)ethanesulfonic acid (MES), 
ethylenediaminetetraacetic acid (EDTA) and polyethylenimine (PEI, Mw 25 kD) were 
purchased from Sigma-Aldrich (St. Louis, MO).  Sodium chloride (NaCl), potassium 
chloride (KCl), sodium phosphate dibasic (Na2HPO4), potassium phosphate monobasic 
(KH2PO4), tetrahydrofuran (THF) and dimethylformamide (DMF) were from Fisher 
Scientific (Pittsburgh, PA).  Platinum/iridium (Pt/Ir) and silver (Ag) wires were 
products of A-M Systems (Sequim, WA).  Lactate oxidase was obtained from Genzyme 
(Cambridge, MA).  Copper nanoparticles (80 nm) were from Inframat Advanced 
Materials (Farmington, CT).  Polydimethylsiloxane (PDMS) was purchased from NuSil 
(Metamora, MI).  Polyurethane (PU) Tecoflex SG-80A, Tecophilic SP-93A-100 and 
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Tecophilic SP-60D-60 were from the Polymer Technology Group (Berkeley, CA).  
Cu(II)-cyclen-PU of Tecophilic SP-93A-100 was synthesized as described previously [2].  
Cu(II)-cyclen-PU of Tecophilic SP-60D-60 was provided by Accord Biomaterials (Ann 
Arbor, MI).  3,3'-Diselenidedipropionic acid (SeDPA) and S-nitrosoglutathione (GSNO) 
were synthesized as described elsewhere [6]. 
 
4.2.2  Fabrication of Implantable Glucose/Lactate Sensors Coated with 
Cu(II)-Cyclen-PU or Cu
0
 Nanoparticle-Doped PU 
 
The fabrication of the needle-type glucose/lactate sensors was based on previous 
publications [9-11] and the details are described in Chapter 3.  Sensors with NO 
generation were loop cast with 10 µL of 4% (w/v) of Cu(II)-cyclen-PU dissolved in THF.  
Both Tecophilic SP-93A-100 (100% water uptake) and Tecophilic SP-60D-60 (60% 
water uptake) derivatized Cu(II)-cyclen-PUs were tested as the outer coatings for glucose 
and lactate sensors.  To obtain sensors with the desired linear range for glucose or 
lactate measurements, multiple layers were coated onto sensors by drying for 30 min in 
between.   
 
For coatings of PU doped with Cu
0
 nanoparticles, 20 % (w/w) of 80 nm Cu
0
 
nanoparticles were dispersed in ca. 4% (w/v) of 3:1 PU and PDMS dissolved in THF with 
2% DMF.  The suspension was sonicated for 1 h before being loop cast onto glucose 
sensors.  Figure 4.3 shows the configuration of NO generating glucose/lactate sensors 
with Cu(II)-cyclen-PU or PU doped with Cu
0
 nanoparticles. 




Figure 4.3.  Configuration of glucose/lactate sensors with Cu(II)-based NO generation 
coatings. 
 
4.2.3  Preparation of Organoselenium Immobilized PEI (SePEI) 
 
The SePEI polyelectrolyte was synthesized according to the procedure proposed 
earlier [6, 7].  Briefly, 28 mg of SeDPA was first activated with 143 mg of EDC and 58 
mg of NHS.  The mixture was then allowed to react with PEI in MES buffer (pH = 6.0) 
for 2 h.  The reaction solution was then centrifuged in an Amicon® centrifugal filter 
unit (MWCO = 3 kD, Millipore Corp., Billerica, MA) at 4,000 rpm for 40 min to remove 
any unreacted reagents.  Afterwards, NaBH4 was used to reduce the resulting yellow 
SePEI solution to break any diselenide crosslinking bonds to free selenol (RSeH) sites.  
The resulting mixture was then exhaustively dialyzed using dialysis membrane 
(Spectra/Por
®
 7, MWCO = 3.5 kD, Spectrum Laboratories Inc., Rancho Dominguez, CA) 
in 50 mM NaCl for 3 d to liberate any unreacted –SeC2H4COOH functional groups.  
The NaCl solution was changed every 12 h.  During the dialysis process, the reduced 
RSeH sites were oxidized back to diselenide (RSe-SeR) by ambient oxygen thus 
crosslinking PEI chains.  The product solution was centrifuged and concentrated into a 
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yellow viscous solution and then stored at 4 °C until future use.  Figure 4.4 illustrates 
the entire synthesis route.  
 
 
Figure 4.4.  Schematic of SePEI synthesis by an EDC/NHS coupling reaction between 
SeDPA and PEI.  
 
4.2.4  LbL Deposition of SePEI/Alg Bilayers onto Glucose Sensor 
 
A glucose sensor was first fabricated and coated with ca. 4% 3:1 PU and PDMS 
solution in THF with 2% of DMF, and finally 100 bilayers of SePEI/Alg were deposited 
via the LbL method.  Both SePEI and Alg polyelectrolytes were made into 1 mg/mL 
solutions in PBS (0.01 M, pH 7.4).  The LbL deposition process was carried out with a 
homemade Lego automatic robot system (Fig. 4.5).  The glucose sensors were 
81 
 
alternatingly immersed into SePEI and Alg solutions for 10 min each.  In between the 
polycation and polyanion layers, the sensors were extensively washed 3 times by 
immersing into 3 beakers of PBS for 1 min.  Figure 4.5 shows the LbL deposition 
process of coating bilayers of SePEI/Alg onto glucose sensors.  The arm rotates and 
immerses sensors into beakers one by one.  After each cycle, the arm turns half a circle 
and starts by dipping sensors into the SePEI solution again.  One hundred SePEI/Agl 
bilayers were coated onto glucose sensors, taking about 2 days to complete.  Figure 4.6 
shows the configuration of the NO generating SePEI/Alg coated glucose sensor. 
 
 





Figure 4.6.  Configuration of NO generating glucose sensor with SePEI/Alg bilayers on 
the outermost surface. 
 
4.2.5  NO Generation Measurements 
 
Nitric oxide generated from coated sensors was monitored via a 
chemiluminescence method with a Sievers Nitric Oxide Analyzer (NOA) 280i (Boulder, 
CO).  A stock solution of GSNO was prepared by mixing 5 mM of GSH and 5 mM of 
NaNO2 in the presence of 60 mM of H2SO4, as previously described [6].  GSNO was 
used as a representative example of all the endogenous RSNO species.  The sensors 
with NO generating coatings were immersed in PBS (pH 7.4) with 5, 10 or 50 µM of 
GSNO and the NO flux data were collected.  The high GSNO concentration of 50 µM 
was used to observe the overall NO generation ability of different catalysts, and lower 
concentrations were used to mimic the endogenous RSNO levels.  EDTA was added in 
the solution in order to bind with any trace metal ions so that they cannot catalytically 
decompose GSNO in the solution.  The sensors were taken out of the solution after the 
NO flux reached a steady-state.  After the signal returned to the baseline, the sensors 
were immersed again into the solution.  Such up-and-down measurements were taken 
three times to obtain an average of the generated NO flux from the Cu- or Se-based 
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polymers.  The stability of NO generation coatings was monitored by collecting NOA 
data over a 7-day period.  
 
4.2.6  In Vitro and In Vivo Testing of NO Generating Glucose/Lactate Sensors 
 
The calibration of NO generating glucose and lactate sensors was similar to the 
method described in Chapter 3.  The sensors were calibrated on a 4-channel BioStat 
potentiostat (ESA Biosciences Inc., Chelmsford, MA).  A potential of +600 mV vs. 
Ag/AgCl reference was applied onto the sensors in 0.1 M PBS, pH 7.4, at 37°C and the 
output current was measured.  The stability of NO generating glucose/lactate sensors 
was tested by calibrating the sensors over one week and monitoring the sensitivity 
change.   
 
Preliminary in vivo experiments of NO generating glucose sensors coated with 
SePEI/Alg bilayers were carried out following the protocol described in Chapter 3.  One 
NO generating glucose sensor with 100 bilayers of SePEI/Alg, one control glucose sensor 
with 100 bilayers of PEI/Alg without any Se species linked to the PEI and one control 
sensor with only PU were implanted in rabbit veins for 8 h.  The accuracy of the 
continuous glucose response was monitored and at every 30 min interval, when 0.6 mL of 
blood was drawn and the blood glucose level was measured by a 700 Series Radiometer 
blood analyzer (Radiometer America Inc., Westlake, OH).  All three sensors were 
explanted after 8 h of implantation and the thrombus formation was observed and 
compared.    
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4.3  Results and Discussion 
 
4.3.1  NO Generating Glucose Sensors with Cu(II) Polymeric Coatings 
 
Figure 4.7 shows the typical NO generation profile of glucose sensors coated with 
PU doped with 20 wt% of Cu
0
 nanoparticles in 0.1 M PBS, pH 7.4, in the presence of 50 
µM GSH, GSNO and EDTA.  When the sensor was immersed into the solution, there 
was an increase in the NO flux, and when the sensor was taken out of the solution the NO 
flux dropped nearly to baseline.  The repeated insertion/removal of the sensor 
demonstrates that the outer polymer can generate a comparable steady-state NO flux after 
each immersion and removal from the test solution.  As a result, such glucose sensors 
are potentially able to generate NO from endogenous RSNO species when implanted in 
blood or subcutaneously.  Improved biocompatibility of the implantable sensors from 






Figure 4.7.  NO generation profile of glucose sensors coated with 20 wt% Cu
0
 
nanoparticles in 0.1 M PBS, pH 7.4, with 50 µM of GSH, GSNO and EDTA.   
 
Table 4.1 summarizes the NO generation properties of the Cu(II)-cyclen-PU (both 
derived from Tecophilic SP-93A-100 and SP-60D-60) and Cu
0
 nanoparticle-doped PU 
materials as sensor coatings.  Firstly, it was noticed that the amount of NO generated 
was proportional to the RSNO levels in the solution, as the higher concentrations of 
GSNO elicited greater NO fluxes than lower GSNO levels.  Secondly, the NO flux 
increased when the amount of Cu catalyst increased, and the Cu
0
 nanoparticle-doped PU 
had the highest NO flux with a much greater Cu content than Cu(II)-cyclen-PUs.  Two 
layers of Cu(II)-cyclen-PU also resulted in a higher NO flux than a single layer, which 
also showed that incresed Cu content results in a greater NO flux.  However, the 
Cu(II)-cyclen-PU derived from Tecophilic SP-60D-60 showed the lowest NO flux, 
although it had a slightly higher Cu content (based on elemental analysis) than the 
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Cu(II)-cyclen-PU derived from Tecophilic SP-93A-100.  This result also indicated that 
the Cu(II)-cyclen-PU derived from Tecophilic SP-93A-100 was more hydrophilic which 
allowed for more GSNO in the solution to diffuse into the polymer and be effectively 
decomposed by all the Cu(II) sites.  Unfortunately, this hydrophilic property contradicts 
the requirement of a hydrophobic polymer to limit glucose/lactate diffusion, and this will 
be discussed later in this section.  As described above, the Cu
0
 nanoparticle-doped PU 
proved to be the most effective catalyst to generate the highest amount of NO from the 
tested RSNO concentrations.  
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Figure 4.8 shows a typical calibration curve of the NO generating glucose sensor 
using the Cu(II)-cyclen-PU derived from Tecophilic SP-60D-60 as the coating.  
Unfortunately, this Cu(II)-cyclen-PU had little catalytic ability in generating NO from 
RSNOs, possibly due to the hydrophobicity of Tecophilic SP-60-D-60, thus limiting the 
diffusion of RSNO species into the polymer to react with the Cu(II) sites, resulting in a 





                  (a)                                 (b) 
Figure 4.8.  Calibration curve of the NO generating glucose sensor with 
Cu(II)-cyclen-PU (SP-60D-60) in 0.1 M PBS, pH 7.4, at 37°C. 
 
Table 4.2 summarizes the analytical performance of glucose sensors coated with 
the three different types of polymers containing Cu catalytic sites.  It was observed that 
the glucose sensors did not have as wide of a linear range when coated with 
Cu(II)-cyclen-PU derived from Tecophilic SP-93A-100, compared to sensors coated with 
more hydrophobic PUs (see Chapter 3).  This was largely due to the hydrophilicity of 
Tecophilic SP-93A-100, which did not limit glucose diffusion well enough to achieve the 
required linear range for high blood glucose detection.  Thus, multiple layers of such 
polymer coatings were deposited onto glucose sensors, in the hope that a thicker 
membrane can further limit the glucose diffusion.  Indeed, the linear range was wider 
when more than one layer of Cu(II)-cyclen-PU derived from SP-93A-100 was coated on 
the glucose sensors.  However, the glucose response time also doubled with this 
increased thickness of the membrane.  As a result, Cu(II)-cyclen-PU was not the optimal 
NO generating coating for glucose sensors because of the conflict between the need for 
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hydrophilicity to achieve more efficient NO generation and that of hydrophobicity to 
achieve a wider linear response range toward glucose.  In the case of Cu
0
 
nanoparticle-doped PU, the glucose sensors preserved normal analytical performance, as 
well as excellent NO generation capability.  As a result, this polymer coating seems to 
be optimal for fabricating Cu-based NO generating glucose sensors.              
       
Table 4.2.  Comparison of NO generating glucose sensors with different Cu polymers. 
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4.3.2  NO Generating Lactate Sensors with Cu(II) Polymeric Coatings 
 
The Cu(II)-cyclen-PU derived from Tecophilic SP-93A-100 was coated onto 
lactate sensors.  Figure 4.9 shows the NO generation profile of the lactate sensor coated 
with four layers of such Cu(II)-cyclen-PU in 0.1 M PBS, pH 7.4, in the presence of 50 
µM each of GSH, GSNO and EDTA.  When the sensor was inserted into the buffer 
solution, there was an increase in the NO flux and this flux reached a steady-state.  
When the sensor was taken out of the solution, the NO flux decreased but a much higher 
baseline was observed, which might be due to the leaching of Cu species into the solution.  
The higher baseline was not observed on glucose sensors coated with Cu(II)-cyclen-PU 
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because the number of coated layers was smaller, so the leaching of Cu species was less.  
This up-and-down of the NO flux signal demonstrates that the outer polymer coatings can 
generate NO after each immersion in the solution with GSNO.  However, the actual 
leaching of Cu species needs to be minimized for in vivo applications. 
 
 
Figure 4.9.  NO generation of lactate sensors coated with four layers of 
Cu(II)-cyclen-PU (SP-93A-100) in 0.1 M PBS, pH 7.4, with 50 µM each of GSH, GSNO 
and EDTA at 37°C. 
 
Figure 4.10 shows an example of the calibration curve of the NO generating 
lactate sensor and Table 4.3 shows the analytical performance as well as the NO flux of 
lactate sensors with varying numbers of Cu(II)-cyclen-PU layers.  Unlike glucose, 
lactate seems to be more permeable in the Tecophillic SP-93A-100 PU matrix, so as 
many as four layers of PU coatings did not change the response time significantly, with 
negligible effect on the linear range.  On the other hand, the goal for the detection range 
for lactate in blood is up to around 5 mM, which is much lower than that of glucose.  As 
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a result, the linear range of lactate sensors with Cu(II)-cyclen-PU Tecophillic 
SP-93A-100 is acceptable for future in vivo studies.  However, the NO flux of such 
Cu(II)-cyclen-PU coatings, in the presence of high concentrations (50 µM) of GSNO, 
barely reached the NO levels required to eliminate thrombus formation from the in vivo 
experiment results as described in Chapter 3.  To make such coatings anti-thrombotic as 
expected, additional infusions of RSNO species are likely needed for future biomedical 
applications.         
 
 
                   (a)                                 (b) 
Figure 4.10.  Calibration curve of the NO generating lactate sensor. 
 
Table 4.3.  Characteristic comparison of NO generating lactate sensors with multiple 
layers of Cu(II)-cyclen-PU. 
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NO Flux with 












2 ~ 1.7 0 – 5 






4.3.3  NO Generating Glucose Sensors with SePEI/Alg LbL Coatings 
 
NO generating coatings of SePEI/Alg via LbL deposition were successfully 
applied to glucose sensors with a PU/PDMS outer coating.  As shown in Figure 4.11, 
when the glucose sensor with 100 SePEI/Alg bilayers was placed into a pH 7.4 PBS 
solution with 10 µM each of GSNO, GSH and EDTA, a burst of NO was detected and the 






).  When 
the sensor was removed from the solution, the NO signal returned close to the original 
baseline, demonstrating the catalytic property of the bilayers with Se sites to liberate NO 
from GSNO.  The repeated insertion/removal of the sensor demonstrated that the 
SePEI/Alg bilayers can generate a comparable steady-state NO flux after each immersion 
and removal from the test solution.  The stability of such 100 bilayers of SePEI/Alg 
coatings was also examined and the results are shown in Figure 4.12.  It can be seen 
from the graph that 100 bilayers exhibited excellent NO generating properties such that 
the generated NO remained relatively stable over a one week period, with a slight 
increase in the NO flux likely due to the conditioning of the bilayers.  Compared to the 
Cu
0
 nanoparticle-doped PU coatings, the 100 bilayers of SePEI/Alg can generate similar 
levels of NO at a relatively low GSNO concentration.  As a result, the SePEI/Alg 
bilayer is a promising candidate coating to enhance the biocompatibility of implantable 
glucose sensors via NO generation from endogenous RSNO species. 




Figure 4.11.  Nitric oxide generation profile of glucose sensors with 100 bilayers of 
SePEI/Alg in 0.01 M PBS with 10 µM each of EDTA, GSH and GSNO at 37°C. 
 
 
Figure 4.12.  Stability of NO generation from glucose sensors with 100 bilayers of 
SePEI/Alg over one week (n=4). 
 
Fortunately, this new NO generating chemistry is compatible with glucose 
sensing.  Figure 4.13 shows an example of the calibration curve of the NO generating 
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glucose sensor prepared with the LbL coating.  At the same time, the entire sensor can 
generate reasonable levels of NO at the surface in the presence of GSH and GSNO.  The 
NO generating glucose sensors showed excellent analytical performance in comparison to 
control sensors without any NO LbL generating coatings, indicating that the SePEI/Alg 
bilayers did not have any negative influence on the glucose sensing chemistry.  Such 
NO generating glucose sensors also remained relatively stable in their sensitivity to 
glucose over a one week period, as shown in Figure 4.14, with two individual sensor 
examples.   
 
 
                  (a)                               (b) 
Figure 4.13.  Amperometric response (a) and corresponding calibration curve (b) of the 





Figure 4.14.  Stability of two individual NO generating glucose sensors prepared with 
100 bilayers of SePEI/Alg over one week in terms of sensitivity. 
 
4.3.4  In Vivo Testing of NO Generating Glucose Sensors with SePEI/Alg Bilayers 
 
Preliminary animal studies of this new NO generating glucose sensor design were 
carried out by implanting one sensor with 100 bilayers of NO generating SePEI/Alg, one 
control with 100 PEI/Alg bilayers without NO generating Se sites and another control 
with bare PU/PDMS into rabbit veins for 8 hours and two separate rabbit experiments of 
this type were carried out.  The animal experiment protocol was followed as described 
elsewhere [12] and in Chapter 3.  Every 30 min, 0.6 mL of blood samples were drawn 
and the blood glucose concentration was measured using a bench-top Radiometer 
instrument and compared to the continuous output from implanted glucose sensors.  
Unfortunately, as shown in Figure 4.15, the expected thrombus resisting property from 
NO generated by Se from endogenous RSNO species was not observed from the 
explanted sensors after the 8 h implantation.  All of the implanted sensors in both rabbit 
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experiments formed obvious thrombus after the 8 h of implantation in rabbit veins.  This 
might be due to the low endogenous RSNO concentrations in the micromolar range or 
less in the rabbit blood stream.  In accordance with the thrombus formation results, all 
the glucose sensors showed deviations from the in vitro measurements by the Radiometer, 
as shown in Figure 4.16.  The deviation might be due to the thrombus formation with 
time which disturbed local glucose diffusion into the sensor within blood vessels so that 
the implanted sensors were not reporting the glucose levels in the bulk of the blood 
stream.  As a result, this SePEI/Alg coating might realize expected anti-thrombus 
function only in the situation where infusions of RSNO species into blood stream is 
feasible, in order to generate high enough fluxes of NO on implanted sensor surfaces.  
This would be possible only in limited biomedical situations. 
 
 
Figure 4.15.  Picture of thrombus formation on the surface of glucose sensors implanted 




Figure 4.16.  Continuous glucose monitoring results from implanted NO generating and 
control sensors with comparison to the bench-top Radiometer readings, from one of the in 
vivo rabbit experiments. 
 
4.4  Conclusions 
 
Implantable glucose/lactate sensors have been fabricated with various NO 
generating coatings, including Cu(II)-cyclen-PUs, PU doped with Cu
0
 nanoparticles and 
SePEI/Alg bilayers.  All of the coatings exhibited NO generation properties via 
catalytically generating NO from RSNO species.  Both SePEI/Alg bilayers and PU 
doped with Cu
0
 nanoparticles showed the best NO generation efficiency.  Coatings of 
Cu(II)-cyclen-PUs on glucose sensors did not provide the sensor with a wide enough 
linear range, while the same coating on lactate sensors maintained an acceptable lactate 
detection range.  Coatings of PU doped with Cu
0
 nanoparticles and SePEI/Alg bilayers 
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did not have any negative influence on the glucose sensing performance, thus enabling 
the potential biomedical applications of such sensors with anticipated anti-thrombus 
property.  However, preliminary in vivo experimental results of glucose sensors coated 
with 100 bilayers of SePEI/Alg indicated that thrombus occurs, suggesting that generated 
levels of NO were inadequate, likely because of low endogenous levels of RSNO species.  
Only two animal experiments were conducted, so it is impossible to make conclusions, 
since if more animals were tested, and they had higher endogenous RSNO levels, results 
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GLUCOSE MEASUREMENT IN HUMAN TEARS USING THE NEEDLE-TYPE 
GLUCOSE SENSOR 
 
5.1  Introduction 
 
Glucose monitoring technologies have drawn significant attention over the past 
several decades to help in the management of diabetes, which afflicts about 5% of the 
world’s population [1].  Tight glycemic control is critical to the care of patients with 
diabetes especially to prevent complications such as cardiovascular disease [2].  It is 
recommended that blood glucose levels be measured several times a day, which usually 
requires finger pricking coupled with measurement using a strip-test type glucometer 
(with either optical or electrochemical readout).  However, in practice, patients may not 
follow these recommendations, and this might be largely due to the accumulated pain 
from the repeated finger pricks and blood collection.  
 
A number of studies have been carried out to find a less invasive means to 
monitor blood glucose levels, including the use of infrared spectroscopy [3, 4], a 
GlucoWatch design that is based on electro-osmotic flow of subcutaneous fluid to the 
surface of the skin and detection of glucose with enzyme-electrode system [5], and 
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measurement of tissue metabolic heat conformation [6], but none of these techniques 
have yielded the quality of analytical results required to become a full substitute for blood 
glucose measurements [7].  Other investigations have suggested testing glucose in tear 
fluid as a substitute for blood, and this concept dates back to the 1950’s [8].  This 
approach provides a unique possibility of developing a relatively simple non-invasive 
method of detecting glucose, if it can be clearly shown that tear glucose levels correlate 
closely with blood glucose values.  If a good correlation between the two types of 
samples can be established, measurement of tear glucose levels could provide an 
attractive indirect measurement method for blood glucose levels within the normal as 
well as hyperglycemic and hypoglycemic ranges.  For such a method to be effective, 
tear fluid needs to be collected using a non-stimulating method [9] so that increases in 
tear production do not further dilute out the naturally present glucose.  At the same time, 
it is important to sample the tear fluid without inflicting any damage to blood capillaries 
within the eye, which might result in tear samples with much higher levels of glucose 
than actually present in the neat tear fluid sample (see below).   
 
Research has been conducted by a number of groups to develop detection 
methods for measuring the levels of glucose in tears.  The requirements of tear glucose 
detection include a low detection limit (i.e., µM range), high selectivity over 
interferences such as ascorbic acid and uric acid, and the ability to measure small sample 
volumes as tear fluid can only be collected via a few microliters at a time.  Published 
methods include capillary electrophoresis (CE) coupled with laser-induced fluorescence 
(LIF) [10], fluorescence sensors [11], liquid chromatography (LC) coupled with 
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electrospray ionization mass spectrometry (ESI-MS) [12], holographic glucose sensors 
[13], a miniaturized flexible thick-film flow-cell detector [14], and a strip-type flexible 
biosensor [15].  Badugu et al. [16, 17] also reviewed the feasibility of using disposable 
contact lenses to monitor glucose through ophthalmic detection.  They suggested that 
this new approach can be considered as a significant alternative to diabetes care and 
management because many diabetics require vision correction and already wear contact 
lenses.   
 
Using an enzymatic method, it was found in the 1980’s that tear glucose levels 
were significantly higher in diabetic patients with higher blood glucose levels than 
normal patients [18].  However, levels of glucose in tears have been found to be 
typically 30-50 times lower than in blood.  Baca et al. recently reviewed studies of the 
correlation between blood and tear glucose levels using different detection methods [9], 
and concluded that there is evidence of a correlation between average tear and blood 
glucose concentrations, but further characterization and justification is needed from 
animal and human studies to determine the potential utility of tear glucose measurements 
to help achieve glycemic control.  In a recent paper, the correlation between the tear 
glucose concentrations and the average blood glucose concentrations was found to be 
stronger for non-contact lens wearers than for participants wearing contact lenses by 
using an LC-MS glucose detection method [12].  However, previous studies of critically 
ill patients using a high performance liquid chromatography method with pulse 
amperometric detection (HPLC-PAD) to monitor tear glucose showed no significant 
correlation between tear and blood glucose concentrations [19].  As a result, further 
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research is needed to evaluate whether measuring tear glucose concentrations can be 
considered a reasonable substitute for blood glucose monitoring.  
 
In this chapter, a relatively simple needle-type amperometric enzyme electrode 
for glucose is described that is capable of measuring the levels of glucose in tear fluid 
down to 1.5 µM, within a capillary tube containing ca. 5 µl of tear fluid.  The sensor is 
utilized to assess the correlation between tear glucose levels and blood glucose 
concentrations in anesthetized rabbits.  It will be shown that measurements with the 
electrochemical device suggest reasonably good correlation between the two types of 
samples within a given animal; however, the ratio between tear glucose and blood 
glucose is found to vary considerably from animal to animal.  
 
5.2  Experimental 
 
5.2.1  Materials 
 
Glucose oxidase (Type VII, From Aspergillus niger), d-(+)-glucose, 
glutaraldehyde, bovine serum albumin (BSA),  sodium chloride (NaCl), potassium 
chloride (KCl), sodium phosphate dibasic (Na2HPO4), potassium phosphate monobasic 
(KH2PO4), iron (III) chloride (FeCl3), 37 % hydrochloric acid (HCl), L-ascorbic acid, uric 
acid, Nafion (5 wt % solution in a lower aliphatic alcohols/H2O mix), 
1,3-diaminobenzene, and resorcinol, were all purchased from Sigma-Aldrich (St. Louis, 
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MO).  Platinum/iridium (Pt/Ir) and silver (Ag) wires were products of A-M Systems 
(Sequim, WA).   
 
5.2.2  Fabrication of Tear Glucose Sensor  
 
The design of the tear glucose biosensor (see Figure 5.1) was based on previous 
configurations used to prepare electrochemical sensors suitable for subcutaneous 
measurements of glucose [20, 21].  Briefly, a 10-cm long Teflon-coated Pt/Ir wire of 0.2 
mm outer diameter was cut and a 1 mm cavity was created (by stripping the Teflon) at 4 
mm from one tip.  Starting 1.5 mm above the opening, a 15 cm, 0.1 mm o.d. silver/silver 
chloride (Ag/AgCl) wire was tightly wrapped around the sensor covering a length of 4 
mm.  The Ag/AgCl wire was prepared by dipping the Ag wire into a 1 M FeCl3 in 0.1 M 
HCl solution.  The straight section above the wrapped Ag/AgCl wire was then covered 






Figure 5.1.  Configuration of the tear glucose sensor in capillary. 
 
Inner polymeric layers deposited on the Pt electrode were used to eliminate 
interferences from ascorbic acid and uric acid.  First, the cavity was coated with a thin 
layer of Nafion (ca. 5 µm thick).  Then, electropolymerization of a solution containing 
1.5 mM 1,3-diaminobenzene and a similar concentration of resorcinol in PBS buffer (0.1 
M, pH 7.4) was initiated using a Voltammograph potentiostat (Bioanalytical Systems Inc., 
West Lafayette, IN) with a cycling voltage of 0 to +830 mV at a scan rate of 2 mV/s for 
18 h [22].  The enzyme layer was created by first dropping 1 μL of a 3 wt% glucose 
oxidase solution containing also 3 wt% BSA in the cavity along the wire and drying this 
layer for 30 min.  Then, the enzyme was crosslinked by adding 1 µl of 2% (vol/vol) 
glutaraldehyde solution and cured in air for 1 h.  The sensor was then rinsed with 
deionized water and stored in 0.1 M PBS (pH 7.4) buffer for future use.   
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5.2.3  Calibration of Tear Glucose Sensor 
 
The amperometric tear glucose sensors were calibrated using a 4-channel BioStat 
potentiostat (ESA Biosciences Inc., Chelmsford, MA).  The sensors were first polarized 
at a potential of +600 mV vs. Ag/AgCl reference in a vial containing 10 mL of PBS 
buffer solution.  Five microliters of glucose standard solutions (100, 200, 500, 800 and 
1000 μM) prepared in PBS were collected by individual 0.85 mm i.d. glass capillaries 
(World Precision Instruments, Sarasota, FL) and sealed with Critoseal (McCormick 
Scientific, Richmond, IL).  The sensor was then taken out of the PBS, blotted briefly 
with Kimwipes (Kimberly-Clark, GA) to remove excess solution and inserted into the 
capillary so that the solution completely covered the sensing region containing the 
immobilized enzyme (see Figure 5.1).  After a stable current was achieved (typically 
within 2 min), the sensor was rinsed with water three times and then put back into the 
stock PBS buffer to reach the steady-state baseline value in preparation for the next 
measurement within the capillary tubes.  To test the sensor selectivity over interferences, 
standard solutions containing potential interferent species at their maximum possible 
levels in tear fluid [23, 24] (i.e., 100 μM of ascorbic acid, 100 μM of uric acid and 10 μM 
of acetaminophen (based on the dilution factor blood ratio)) were collected in capillaries, 
and the response current for each interferent species was measured.  Based on the 
sensitivity of the sensor to glucose, and the amperometric signal observed for these 
interferent speices, the % error that would occur for samples containing these levels of 
interferences and 100 µM tear glucose were calculated.  To test the repeatability of such 
tear glucose sensor, the device was inserted into five separate capillaries containing 5 µL 
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of 100 μM glucose, with washing and baseline stabilization in PBS buffer in between the 
multiple measurements.  The average reported glucose concentration was determined 
from a prior calibration curve made in capillary tubes using 100, 200, 500, 800 and 1000 
µM glucose standards. 
 
5.2.4  Protocol to Assess Correlation between Tear and Blood Glucose 
Concentrations in Rabbits 
 
Twelve white rabbits (Myrtle’s Rabbitry, Thompson’s Station, TN) were used in 
this study to test the correlation between tear glucose measured with the needle-type 
sensor and blood glucose measured with a Radiometer.  An anesthesia protocol as 
described elsewhere in detail [25] was followed for the experiments with the exception 
that the maintenance fluid rate was adjusted to 3.3 mL/kg/min.  All rabbits were under 
anesthesia for 8 h.  The tear glucose sensor was polarized at +600 mV in PBS buffer 
through the duration of the entire experiment.  The sensor was calibrated in capillary 
tubes with 100 μM glucose in the middle of the 8 hour experiment.  Every 30 min, 0.6 
mL blood was drawn and the blood glucose level was measured using a 700 Series 
Radiometer blood analyzer (Radiometer America Inc., Westlake, OH) that employs a 
macro-electrochemical enzyme electrode to quantitate blood glucose.  At the same time, 
5 μL of rabbit tear fluid was collected in the capillary and the current from the glucose in 
the tear fluid was recorded using the tear glucose sensor.  The tear glucose level was 
calculated from the one point calibration result.  Statistical data analysis was carried out 
to examine the correlation between the blood and tear glucose values within a given 
animal and across all 12 animals involved in the study. 
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5.3  Results and Discussion 
 
5.3.1  The Analytical Performance of Tear Glucose Biosensor 
 
The typical calibration curve for the tear glucose biosensor in capillary tubes is 
shown in Figure 5.2.  The detection limit is 1.5 ± 0.4 μM of glucose (S/N=3).  It should 
be noted that this low detection limit is achieved by not coating the outer surface of the 
sensor with an additional membrane that restricts diffusion of glucose to the enzymatic 
layer.  Such an additional coating is required for blood and subcutaneous glucose 
sensing in order to ensure that oxygen is always present in excess compared to glucose in 
the enzymatic layer to achieve linear response to high glucose concentrations.  However, 
given the much lower levels of glucose in tear fluid, no outer membrane is needed to 
retard glucose diffusion, since oxygen levels will be always in excess in such samples.  
This ultimately enables the very low detection limit of the sensor.  The glucose sensor 
design employed in this work has an average sensitivity of 0.019 ± 0.009 nA/μM of 
glucose (n=4).  The linear range can reach to 1000 μM which is nearly 10-fold greater 
than the average normal value of 138 μM found previously for tear glucose levels in 
humans [10].  From the repeatability test of the tear glucose sensors, they showed an 
acceptable repeatability with an average of 102.5 ± 3.2 µM measured for the 5 
measurements in individual capillaries containing ca. 5 µl of 100 µM glucose solution, 





                 (a)                                (b) 
Figure 5.2.  Amperometric response of tear glucose sensor using 5 μL solution in 
capillary.    (a) Solutions in the order of 100 μM ascorbic acid, 100 μM uric acid, 10 
μM acetaminophen, 100 μM, 200 μM, 500 μM, 800 μM and 1000 μM glucose solution.  
(b) Calibration curve of tear glucose sensor.  
 
 
Figure 5.3.  Repeatability test of 5 measurements in individual capillaries containing ca. 
5 µl of 100 µM glucose solution, each. 
 
Any glucose sensor designed for measurements in physiological tear fluid must 
exhibit acceptable selectivity over existing electroactive species typically present in tears.  
At the potential of +600 mV vs. Ag/AgCl reference electrode, those interferences might 
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also be oxidized at the working electrode used to detect the hydrogen peroxide generated 
from glucose oxidase reaction with glucose, adding error to the output current.  It has 
been reported in the literature that ascorbic and uric acid concentrations in tear fluid are 
ca. 20 and 70 μM, respectively [23, 24].  As a result, 100 μM of both ascorbic acid and 
uric acid were used to test the selectivity of the tear glucose sensor.  For small neutral 
molecule interferences, 10 μM of acetaminophen was employed for testing, assuming that 
this species would be present in tear fluid at levels similar to the relative dilution ratio of 
blood glucose levels.  The error percentage was calculated by dividing the current of 
certain interference by that observed for a 100 μM standard of glucose.  The presence of 
the Nafion and electropolymerized 1,3-diaminobenzene/resorcinol inner layer enabled the 
sensor to exhibit excellent exclusion of interferences with the % errors for ascorbic acid, 
uric acid and acetaminophen of 6.45 ± 4.06, 3.75 ± 2.88 and 3.55 ± 1.76%, respectively 
(n=4).  These results indicate that the tear glucose biosensor has acceptable selectivity 
over major electroactive interferences found in tear fluid and that results obtained for tear 
samples will likely reflect the true level of glucose present in such samples.   
 
5.3.2  Correlation of Tear Glucose and Blood Glucose from the Rabbit Model 
 
Figures 5.4(a) and (b) show the Pearson’s correlation between tear and blood 
glucose from 2 individual rabbit experiments.  The determined r
2 
values are 0.9126 and 
0.8894, respectively (p<<0.05), indicating significant correlation between tear and blood 
glucose concentrations.  Both examples show excellent fitting to the linear regression 
model.  Figure 5.4(c) shows all the blood-tear glucose values from the twelve rabbit 
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experiments.  There seems to be a low correlation between blood and tear glucose 
concentrations when the data from all animals tested are combined, based on the results 
obtained using Pearson’s correlation analysis (r
2
=0.4867, p<<0.05).  Furthermore, it is 
difficult to establish a simple mathematic function model, such as a linear relationship, 
between the tear and blood values for the entire data set.  This is due to the fact that 
there was a significant difference in the correlations for individual rabbits.  This implies 
that even though the tear and blood glucose levels in each rabbit demonstrate a 
reasonable linearity in correlation, the variation among individual animals undermines 
this general trend as a whole, and this resulted in a low global tear-blood glucose 
correlation.   
 
It should be noted that there is a common trend of blood and tear glucose 
concentration decay from the beginning of the 8 h experiment for all the rabbits tested.  
As a result, average values of both blood and tear glucose values can be taken at each 
half-hour time point.  The shared trend of glucose decay in both blood and tear glucose 
values, indicates that the blood and tear glucose levels increase or decrease in tandem.  
Figure 5.4(d) shows the average of blood-tear glucose levels at thirty minute increments.  
A Pearson’s correlation analysis reveals a significant relationship between tear and blood 
glucose concentrations (r
2
=0.9475, p<<0.05) and a linear regression shows excellent 
fitting.  Using a 2
nd
 order polynomial correlation, the fitting model between tear and 
blood glucose levels is even better (r
2
=0.9835) (Figure 5.4(e)).  Although this fitting 
shows a slightly higher correlation coefficient, it makes the model one order more 
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complex, with only slight gains.  As a result, in future applications, the linear model can 
still be used with acceptable accuracy. 
 
 
                   (a)                              (b) 
 
                   (c)                               (d)  
 
                                   (e) 
Figure 5.4.  Correlation between tear and blood glucose levels using a rabbit model.  
(a) & (b) Results from two individual rabbit experiments.  (c) All the data points of tear 
and blood glucose values for the total of 12 rabbits.  (d) The average values of both tear 
and blood glucose levels for all animals in study at every half hour time point.  (e) A 2
nd
 
order polynomial correlation between average tear and blood glucose levels. 
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In the potential real-world application of the biosensor method for monitoring 
glucose levels of diabetic patients, after the correlation between tear and blood glucose 
levels for each individual is established (presuming, like rabbits, the exact correlation and 
dilution factor from patient to patient may vary), an abnormal tear glucose concentration 
range can be set up to detect dangerous blood glucose levels from the correlation.  Thus, 
tear glucose levels can be measured multiple times per day to monitor blood glucose 
changes without the potential pain from the repeated invasive blood drawing method.  
Indeed, blood glucose levels can still be measured using the traditional blood collection 
method in order to trigger proper therapy when tear glucose detection suggests that blood 
glucose levels are out of the normal range.  
 
5.4  Conclusions 
 
A simple electrochemical tear glucose biosensor coupled with a tear fluid 
collection capillary configuration has been used to monitor glucose levels in tears from 
rabbits.  The needle-type amperometric sensor exhibits excellent selectivity over known 
electroactive interferences, a low detection limit, a wide dynamic range, excellent 
repeatability and at present requires a 4-5 microliter sample volume.  With further 
miniaturization of the sensor diameter, it is likely that measurements in as little as 1-2 µL 
of fluid should be possible, a volume more suitable for routine tear glucose measurements 
in humans.  The correlation between tear and blood glucose levels has been established 
in a rabbit model and data analysis suggests that a significant correlation between tear 
and blood glucose levels does exist, but that the exact correlation varies from animal to 
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animal.  Hence, the use of tears as an alternate sample to assess blood glucose in human 
subjects will likely require that the ratio of glucose in tears and blood be established first 
for a given individual, so that the appropriate algorithm can be employed to report values 
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6.1  Summary of Results for Dissertation Research 
 
Tight glycemic control is beneficial not only for diabetic patients to reduce 
occurrences of complications, but also for non-diabetic critically ill patients to potentially 
achieve improved outcomes [1-5].  Continuous monitoring of blood lactate levels also 
plays an important role in the critical care medical setting.  While the development of 
implantable glucose/lactate sensors has been the focus of many investigators over many 
years, success in this area has been hindered by biocompatibility problems, either 
thrombus formation when sensors are implanted within blood vessels, or encapsulation 
by immune cells when the sensors are implanted subcutaneously.  
 
Nitric oxide (NO) has been found as a potent anti-thrombus and 
anti-inflammatory agent which naturally exists in many cells in the human body [6-10].  
In this dissertation research, efforts have been made to develop intravascular 
glucose/lactate sensors with polymeric coatings capable of releasing NO from doped 
diazeniumdiolates or from generating NO from endogenous blood S-nitrosothiols 
(RSNOs), in the hope of improving the in vivo biocompatibility of the implantable 
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devices.     
 
In Chapter 2, relatively thin NO releasing coatings for potential use as sensor 
coatings were developed using poly(lactide-co-glycolide) (PLGA) as the polymer matrix 
with N-diazeniumdiolated dibutylhexanediamine (DBHD/N2O2) doped as the NO donor.  
Such coatings with a top layer of PurSil can release NO for over one week at 






), which is much longer than previously 
published coatings applied to implantable glucose sensors [11].  The most appropriate 
PLGA type, 50:50 RG 502 H, was chosen for future sensor studies due to its optimal NO 
release characteristics.  The PLGA polymer to DBHD/N2O2 weight ratio was also 
optimized as 2:1. 
 
In Chapter 3, intravascular glucose/lactate sensors with NO release were 
fabricated using the polymeric coatings examined in Chapter 2.  In vitro, the NO release 
sensors showed excellent analytical performance required for real blood sample detection, 
in terms of having stable sensitivity over one week and high selectivity over major 
interferences, such as ascorbic acid.  With the PLGA-based polymer coatings, the 
sensors can release NO on the surfaces at physiologically relevant levels for over 7 days.  
In vivo hemocompatibility of NO releasing glucose sensors was studied by implanting the 
sensors in rabbit veins for 8 hours.  From digital pictures of explanted sensors, control 
sensors without NO release showed obvious thrombus formation on the surfaces while 
NO releasing sensors exhibited much cleaner surfaces, indicating enhanced 
biocompatibility.  A quantitative method to analyze thrombus formation was applied by 
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using Image J software to measure the red pixel area of the pictures of the explanted 
sensors, and this imaging confirmed the enhanced biocompatibility of NO release sensors 
(vs. controls) with statistically significantly less thrombus formation on their surfaces.  
The NO releasing glucose sensors also showed greater accuracy in reporting blood 
glucose levels in comparison to the control sensors as seen in the Clarke error grid 
analysis of the in vivo data, where more glucose values fell into the accurate zones when 
correlated to readings from a bench-top instrument on drawn blood samples from the test 
animals. 
          
In addition to releasing from doped donors, NO can also be catalytically 
generated from endogenous RSNO species.  The NO generating chemistry was applied 
to implantable glucose/lactate sensors and the chemical compatibility was evaluated in 
Chapter 4.  For the copper type catalysts, Cu(II)-cyclen-polyurethanes did not provide 
glucose sensors with a wide enough linear range due to their hydrophilicity, but they did 
not have any negative effects on the analytical performance of lactate sensors.  However, 
the NO flux generated from endogenous levels of RSNOs was low and may not be 
enough to eliminate thrombus formation as expected.  Copper nanoparticle-doped 
polyurethane was compatible with the glucose sensing chemistry and this coating 
exhibited the highest efficiency of catalytically generating NO from RSNOs.  For the 
selenium catalyst, 100 bilayers of organoselenium immobilized polyethyleneimine 
(SePEI) and alginate (Alg) deposited on glucose sensor surfaces also showed a similar 
NO generation capability to that of Cu
0
 nanoparticle-doped polyurethane while 
maintaining the analytical performance of the glucose sensors.  Such coated sensors 
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were implanted in rabbit veins for 8 hours, but the preliminary results did not show the 
expected anti-thrombus property, likely due to the low RSNO levels in blood [12, 13].  
However, since only two rabbits were tested, clear cut conclusions cannot be drawn at 
this point.  Certainly, additional animal testing is needed to make a definitive assessment 
regarding the prospects of using the NO generating coatings on intravascular sensors.  
However, it is possible that the NO generating chemistry can only be applied in the 
situation where infusion of additional RSNOs is feasible in order to generate a high 
enough NO flux so that enhanced biocompatibility can be best realized. 
 
Beyond implantable glucose sensors, tear glucose measurements have shown 
potential as a non-invasive method of monitoring blood glucose levels based on the 
correlation between glucose levels in blood and in tear fluids.  In Chapter 5, a new and 
simple amperometric tear glucose biosensor coupled with a tear fluid collection capillary 
configuration was studied.  The sensor exhibited excellent selectivity over major 
interferences, a low detection limit in the micromolar range, a wide dynamic range (up to 
one millimolar) and only requires ca. 5 µL of sample volume.  The sensors were used to 
monitor glucose levels in tears from rabbits and the correlation between tear and blood 
glucose levels was established.  The data analysis showed a significant correlation 
between tear and blood glucose levels, but the exact mathematic ratio between the two 
values varied from animal to animal.  Hence, the use of tear fluids as an alternate sample 
to monitor blood glucose in human subjects is promising only if the appropriate 
algorithm of glucose in tears and blood can be established first for a given individual.  
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6.2  Future Work 
 
The NO releasing coatings proposed in Chapter 2 showed promising 
anti-thrombotic applications onto other blood-contacting medical devices from the in vivo 
experiment results of NO releasing glucose sensors implanted in rabbit veins for 8 hours 
described in Chapter 3.  Although the first lactate sensor was also formulated with an 
NO releasing coating, it has not yet been evaluated for in vivo performance.  The 
chemistry of NO release using DBHD/N2O2-doped in PLGA did not interfere with the 
lactate sensing chemistry from the data presented in Chapter 3.  As a result, the NO 
releasing lactate sensors implanted in blood vessels are expected to exhibit anti-thrombus 
forming surfaces, similar to NO releasing glucose sensors.  Improved accuracy in 
continuously reporting blood lactate levels from sensors with NO release can also be 
expected compared to control sensors without any NO release. 
 
In Chapters 2 and 3, PLGA was used as the matrix to sustain prolonged NO 
release from doped diazeniumdiolates, taking advantage of the slow hydrolysis process of 
PLGA to control the pH in the polymer.  There are other polymers with anionic sites that 
can also be considered as appropriate matrices for long term NO release including the 
sulfonated polyurethane (PU-SO3), based on the mechanism similar to the use of borate 
additives described in Chapter 2 [14].  The sulfonate anionic groups tethered to the PU 
backbones can also function as counter anions to the ammonium sites formed after NO is 
released from DBHD/N2O2 (Fig. 6.1).  The advantage of using sulfonated PUs is that no 
additives are needed in the polymeric coatings and there are no additional species being 
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introduced to the system which might potentially influence the sensor performance.  
Tecoflex-SO3 was successfully derivatized previously in our group according to a method 
described earlier [15].  Preliminary data of NO release from 33 wt% of DBHD/N2O2 
doped in such a polymer coated on glucose sensors showed a prolonged NO release for 4 
days (Fig. 6.2).  Tecoflex-SO3 is also promising because it did not show any negative 
effect on glucose sensing.  In the future, the optimization of such polymer coatings on 
glucose sensors need to be further studied and such coatings can also be applied onto 
other implantable sensors as well.  Enhanced biocompatibility of those sensors can also 




Figure 6.1  Schematic of sulfonated anionic sites in PU backbones working as counter 






Figure 6.2.  Nitric oxide release of glucose sensors coated with 33 wt% doped 
DBHD/N2O2 in Tecoflex-SO3 over 4 days.  
 
Considering the possibility that low endogenous RSNO levels might not generate 
adequate levels of NO to eliminate thrombus formation when using sensor coatings 
described in Chapter 4 that catalytically generate NO from RSNOs, alternate approaches 
based on using RSNO reservoirs in polymer materials may be needed.  Indeed, RSNO 
species can also be considered as prospective NO donors for long-term NO 
release/generation purposes.  It has been already reported in the literature that 
RSNO-modified xerogel films are able to release physiological levels of NO induced by 
thermal, photolytic, and copper ions [16].  These films also resisted platelet and 
bacterial adhesion because of the NO release.  Thus it should be also be possible to dope 
RSNOs into PLGA films so that NO release can be well controlled for various biological 
applications.  The advantage of using RSNOs is that they are naturally occurring species 
in the human body and hence the combination of NO release via embedded RSNOs and 
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the PLGA matrix will not form any toxic residuals after the NO is released, in 
comparison to the residual DBHD that exists when using diazeniumdiolates as the NO 
donors.  DBHD may ultimately cause some toxicity issues if it is leaches out to any 
degree from the polymer [17].  As a result, PLGA films with doped RSNOs can be 
coated onto many medical devices with expected anti-thrombus and anti-inflammatory 
biological properties, without any concern about potential toxicity. 
 
The glucose sensor proposed in Chapter 5 for tear glucose measurement needs to 
be further miniaturized so that only one microliter of tear fluid is needed for real 
applications.  In that case, it might be difficult to obtain a steady-state amperometric 
current within the capillary due to the small amount of glucose in tear fluid which could 
potentially increase the error of reporting tear glucose concentrations.  One alternative 
approach is to use a coulometric method to measure the total amount of hydrogen 
peroxide (H2O2) generated from the enzyme reaction that would deplete all the glucose in 
the tear sample. This can be accomplished by making the surface area of the sensing 
region larger relative to the volume of tear sample.  In this way, the total amount of 
glucose contained in the tear fluid sample is measured by countying charge, instead of 
reaching some steady state current that can be influenced by thickness of membrane 
coatings, etc.  Indeed, it is likely that the coulometric approach would yield a greater 
degree of accuracy for measuring tear glucose values and such an approach should be 
pursued.          
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